A spot-lightening, mark-lightening, whitening and synergistic composition containing mandelic acid and having targeted transdermal delivery function, and a preparation method and application thereof

Through the combined structure of the internal aqueous phase, oil phase and external aqueous phase, a light spot and light print whitening and efficiency composition targeted to transdermal delivery function is formed, which solves the problem of inaccurate release of whitening active ingredients in the prior art, and realizes the Effective post-pigmentation treatment for acne and reduce side effects.

CN117731544BActive Publication Date: 2024-11-15SHANGHAI JIYAN COSMETICS TECHNOLOGY CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202311755351.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-19
Publication Date
2024-11-15
Estimated Expiration
2043-12-19

AI Technical Summary

Technical Problem

The prior art failed to achieve accurate release when preparing co-delivery nanocompositions containing phenethyl resorcinol, resulting in the failure of whitening active ingredients to play their key role efficiently, and it has more attacks on non-target sites, and has side effects. Larger.

Method used

Using a combined structure of the inner aqueous phase, the oil phase and the outer aqueous phase, the inner aqueous phase includes α-MSH antagonist, and the oil phase includes phenethyl resorcinol, palmitoyl tetrapeptide-7, and acetyl dipeptide-1. The outer aqueous phase includes amygdonic acid and polyglyceride emulsifiers. Through micronization and nanoification treatment, a spot-light-print whitening and enhancing composition targeting the transdermal delivery function is formed.

Benefits of technology

It achieves the precise release of whitening active ingredients, improves bioavailability, reduces attacks on non-target areas, significantly improves the therapeutic effect of post-acne pigmentation, and reduces skin inflammation and irritation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004616930870000161
    Figure BDA0004616930870000161
  • Figure BDA0004616930870000231
    Figure BDA0004616930870000231
  • Figure BDA0004616930870000232
    Figure BDA0004616930870000232
Patent Text Reader

Abstract

The present invention provides a smear-lightening and whitening synergistic composition containing mandelic acid and having a targeted transdermal delivery function. Compared with the prior art, the smear-lightening and whitening synergistic composition provided by the present invention has an outermost layer of an exfoliating active containing a high concentration of mandelic acid, which is released first, and can help to quickly lighten the pigmentation already formed on the epidermis; the inner layer contains a high concentration of phenethyl resorcinol and other whitening active ingredients, which can penetrate into the target site of melanocytes in the basal layer, and effectively play the role of blocking blackening and suppressing blackness at the source; the skin care concept of highly consistent and precise release is achieved through the inner water phase, the oil phase and the outer water phase; in addition, a double anti-allergic peptide is added to the oil phase, which can help reduce the inflammation remaining in acne skin, prevent inflammation-induced pigmentation, and can also help reduce the irritation caused by high concentrations of mandelic acid and phenethyl resorcinol, and reduce the secondary stimulation brought to people with acne skin, thereby helping them to better lighten black acne marks.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of cosmetics, and in particular relates to a spot-lightening, mark-lightening, whitening and synergistic composition containing mandelic acid and having a targeted transdermal delivery function, a preparation method and an application thereof. Background Art

[0002] Acne has become the eighth largest chronic disease in the world. Studies have found that more than 80% of people will have acne to varying degrees in their lifetime. Acne sequelae generally include post-acne scars (moderate to severe acne), post-acne erythema (PIE) (red acne marks) and post-acne hyperpigmentation (PIH) (black and brown acne marks). Among them, post-acne erythema and hyperpigmentation have a higher incidence rate, with erythema as high as 90%, followed by hyperpigmentation, up to 70% (Li Qiaoling, Xue Li, Li Li. Investigation and analysis of influencing factors related to post-acne skin lesions. Chinese Journal of Aesthetic Medicine, 2018, 27(10): 24-26.). Post-acne hyperpigmentation is a pigmentation spot or plaque with a color ranging from brown to black, which is usually left after the erythema of the acne site subsides. Its causes include internal factors such as inflammatory stress such as the inflammatory cascade reaction of the acne site, and external factors such as ultraviolet radiation stimulation. Among them, the degree and depth of the inflammatory stress response and the stability of melanocytes, these factors together lead to the deposition of melanin in the epidermis and dermis.

[0003] The main cause of black acne in acne patients is closely related to inflammation. Many studies have shown that a variety of inflammatory factors can cause melanocytes to be overactive, thereby producing more melanin, such as 1L-1α, 1L-33, PGE2, etc. (Md Razib Hossain, Int J Mol Sci. 2021Apr; 22(8): 3970). In acne patients, pigmentation is the most troublesome sequelae, because after acne patients form black acne marks, most of them exist for a long time. Based on epidemiological surveys and studies, more than 65% of acne patients have pigmentation for more than 1 year (Abad-casintahan et al. J dermatol. 2016: 43: 826-828), and studies have shown that even mild to moderate acne patients can also develop pigmentation. Therefore, for acne patients, timely intervention in the early stage of black acne marks is very important to avoid the formation of stubborn and difficult-to-remove pigmentation.

[0004] Because pigmentation involves multiple influencing factors, in order to solve pigmentation more efficiently, it is generally necessary to cover multiple targets of pigmentation. Common treatment strategies include sun protection, anti-oxidation, cutting off stress signals, inhibiting melanin production and accelerating melanin metabolism. Currently, in the 2019 edition of the Chinese Acne Treatment Guidelines, new treatment recommendations for acne sequelae have been added, among which the recommended medications for post-acne pigmentation mainly cover two target pathways: Pathway 1 is to inhibit melanin production by using some melanin production rate-limiting enzyme inhibitors, such as arbutin drugs; Pathway 2 is to use some drugs with exfoliation effects, that is, to lighten the pigmentation that has already formed on the epidermis, such as retinoic acid drugs, fruit acids, etc.

[0005] The Chinese patent with publication number CN108743430B discloses a co-delivery nanocomposition containing phenethyl resorcinol, which contains phenethyl resorcinol and other whitening active ingredients, and demonstrates through examples that the whitening active ingredients with multiple targets and multiple mechanisms of action have whitening effects. However, in this patent, for phenethyl resorcinol and other whitening active ingredients, the process preparation is simply based on the solubility characteristics of the raw materials themselves for phase separation preparation, such as water-soluble raw materials in the same phase, oil-soluble raw materials in the same phase, and phenethyl resorcinol and exfoliating active ingredients in the same phase, resulting in that it cannot achieve precise release, and the relevant active ingredients fail to play their key role more efficiently. Precise release is extremely critical, both in the medical field and the cosmetic field. On the one hand, it can maximize the release of active ingredients to the target site, fully improve its bioavailability, and then play an efficient role on the target site; on the other hand, it can reduce the attack on other non-target sites and reduce side effects. Summary of the invention

[0006] In view of this, the technical problem to be solved by the present invention is to provide a blemish-lightening, scar-lightening and whitening synergistic composition containing mandelic acid with targeted transdermal delivery function, and a preparation method and application thereof.

[0007] The present invention provides a spot-lightening, mark-lightening, whitening and synergistic composition containing mandelic acid and having a targeted transdermal delivery function, which is formed by an inner water phase, an oil phase and an outer water phase;

[0008] The internal aqueous phase includes an α-MSH antagonist;

[0009] The oil phase includes phenylethyl resorcinol, palmitoyl tetrapeptide-7, acetyl dipeptide-1 cetyl ester, emulsifier, neutral phospholipids and oil;

[0010] The external aqueous phase includes a keratin exfoliant and a polyglycerol ester emulsifier;

[0011] The exfoliating agent includes mandelic acid.

[0012] Preferably, the mass of the α-MSH antagonist is 0.01% to 1% of the mass of the spot-lightening and whitening synergistic composition;

[0013] The mass of the phenethyl resorcinol is 1% to 10% of the mass of the spot-lightening and whitening synergistic composition;

[0014] The mass of the palmitoyl tetrapeptide-7 is 0.01% to 1% of the mass of the spot-lightening and whitening synergistic composition;

[0015] The mass of the acetyl dipeptide-1 cetyl ester is 0.01% to 1% of the mass of the spot-lightening and whitening synergistic composition;

[0016] The mass of the keratin peeling agent is 1% to 10% of the mass of the spot-lightening, mark-removing, whitening and synergistic composition.

[0017] Preferably, the mass ratio of phenethyl resorcinol, palmitoyl tetrapeptide-7 and acetyl dipeptide-1 cetyl ester is (1-10):(0.01-0.5):(0.01-0.5).

[0018] Preferably, the α-MSH antagonist is selected from one or more of nonapeptide-1, undecylenoyl phenylalanine and hexapeptide-2;

[0019] The keratolytic agent also includes salicylic acid and / or capryloyl salicylic acid.

[0020] Preferably, the inner water phase further comprises a first polyol; the outer water phase further comprises a second polyol;

[0021] The first polyol and the second polyol are each independently selected from one or more of glycerol, propylene glycol, butylene glycol, 1,2-pentanediol, 1,2-hexanediol, 1,3-propanediol, dipropylene glycol, PEG-10 propylene glycol and polyethylene glycol-400;

[0022] The mass of the first polyol is 1% to 5% of the mass of the spot-lightening and whitening synergistic composition;

[0023] The mass of the second polyol is 10% to 20% of the mass of the spot-lightening and whitening synergistic composition.

[0024] Preferably, the mass of the emulsifier is 3% to 7% of the mass of the spot-lightening and whitening synergistic composition;

[0025] The emulsifier is selected from one or more of octyl glucoside, arachidyl glucoside, polyglyceryl-10 oleate, polyglyceryl-10 myristate, polyglyceryl-4 oleate, polyoxyethylene hydrogenated castor oil and polysorbate-80;

[0026] The mass of the neutral phospholipid is 1% to 5% of the mass of the spot-lightening and whitening synergistic composition;

[0027] The neutral phospholipid is selected from one or more of lecithin, soybean lecithin, hydrogenated soybean lecithin, dimyristoylphosphatidylcholine, dioleoylphosphatidylcholine, phosphatidylethanolamine, dioleoylphosphatidylethanolamine, cephalin, and sphingomyelin;

[0028] The mass of the oil is 1% to 5% of the mass of the spot-lightening, mark-lightening and whitening synergistic composition;

[0029] The oil is selected from one or more of caprylic / capric triglyceride, palmitic triglyceride, isopropyl palmitate, triethylhexanoin, isopropyl myristate, ethylhexyl cocoate, ethylhexyl palmitate, isoamyl laurate, squalane, olive oil, soybean oil and jojoba seed oil;

[0030] The mass of the polyglycerol ester emulsifier is 1% to 5% of the mass of the spot-lightening and whitening synergistic composition;

[0031] The polyglycerol ester emulsifier is selected from one or more of polyglyceryl-10 myristic acid ester, polyglyceryl-10 oleic acid ester, polyglyceryl-10 dipalmitate and polyglyceryl-10 diisostearate.

[0032] The present invention also provides a method for preparing the above-mentioned spot-lightening, mark-lightening and whitening synergistic composition containing mandelic acid and having a targeted transdermal delivery function, comprising the following steps:

[0033] S1) mixing an α-MSH antagonist with water to obtain an inner aqueous phase;

[0034] Mixing phenylethyl resorcinol, palmitoyl tetrapeptide-7, acetyl dipeptide-1 cetyl ester, an emulsifier, a neutral phospholipid and oil to obtain an oil phase;

[0035] Mixing a keratin exfoliant, a polyglycerol ester emulsifier and water to obtain an external aqueous phase;

[0036] S2) adding the inner water phase dropwise to the oil phase and mixing to obtain a water-in-oil system;

[0037] S3) adding the water-in-oil system dropwise to the external aqueous phase and mixing to obtain a water-in-oil-in-water emulsion;

[0038] S4) micronizing the water-in-oil-in-water emulsion to obtain a micron-sized dispersion;

[0039] S5) performing nano-processing on the micron-sized dispersion to obtain a spot-lightening, scar-lightening, whitening and synergistic composition containing mandelic acid and having a targeted transdermal delivery function.

[0040] Preferably, the dripping speed in step S2) and step S3) is independently 1 to 5 drops / s; the mixing speed in step S2) and step S3) is independently 10 to 60 rpm;

[0041] In the step S4), the micronization treatment is high-speed shearing; the speed of the high-speed shearing is 4000-10000 rpm; the time of the high-speed shearing is 1-10 minutes;

[0042] The nano-treatment in step S5) is a high-pressure homogenization treatment or a high-speed microfluidization treatment; the pressure of the high-pressure homogenization treatment is 300 to 1600 bar; the number of cycles of the high-pressure homogenization treatment is 1 to 10 times; the pressure of the high-speed microfluidization treatment is 5000 to 16000 psi; the number of cycles of the high-pressure microfluidization treatment is 1 to 10 times.

[0043] The present invention also provides a cosmetic comprising the above-mentioned blemish-lightening, mark-lightening and whitening synergistic composition containing mandelic acid and having a targeted transdermal delivery function.

[0044] Preferably, the mass of the spot-lightening, scar-removing, whitening and synergistic composition containing mandelic acid and having targeted transdermal delivery function is 0.01% to 10% of the mass of the cosmetic.

[0045] The invention provides a spot-lightening, mark-lightening, whitening and synergistic composition containing mandelic acid and having a targeted transdermal delivery function, which is formed by an inner water phase, an oil phase and an outer water phase; the inner water phase comprises an α-MSH antagonist; the oil phase comprises phenethyl resorcinol, palmitoyl tetrapeptide-7, acetyl dipeptide-1 cetyl ester, an emulsifier, neutral phospholipids and oils; and the outer water phase comprises a keratin exfoliant and a polyglycerol ester emulsifier. Compared with the prior art, the whitening and synergistic composition for lightening spots and marks provided by the present invention has an outermost layer of an exfoliating active containing a high concentration of mandelic acid, which is released first and can help to quickly lighten the pigmentation already formed on the epidermis, that is, accelerate the lightening of melanin; the inner layer contains a high concentration of phenylethyl resorcinol and other whitening active ingredients, which can penetrate into the target site of melanocytes in the basal layer, and effectively play the role of blocking melanin transformation and suppressing melanin at the source; the skin care concept of highly consistent and precise release is achieved through the inner water phase, the oil phase and the outer water phase, which can help to more efficiently and specifically overcome the pigmentation of people with acne; in addition, a dual anti-allergic peptide is added to the oil phase, which can help to reduce the inflammation remaining in acne skin, prevent inflammation-induced pigmentation, and can also help to reduce the irritation caused by high concentrations of mandelic acid and phenylethyl resorcinol, and reduce the secondary stimulation brought to people with acne skin, thereby helping them to better lighten black acne marks. BRIEF DESCRIPTION OF THE DRAWINGS

[0046] Figure 1 This is a microscopic morphology of the spot-lightening, mark-lightening, whitening and synergistic composition prepared in Example 5 of the present invention;

[0047] Figure 2 The cumulative release percentage curve of phenylethylresorcinol (377) and mandelic acid of the spot-lightening and scar-lightening whitening synergistic composition prepared in Example 5, Comparative Example 1, Comparative Example 9 and Comparative Example 10 of the present invention and the free whitening composition prepared in Comparative Example 3;

[0048] Figure 3 This is a cumulative release percentage curve of phenylethylresorcinol (377) and mandelic acid in the spot-lightening and scar-lightening whitening synergistic composition prepared in Example 5 of the present invention;

[0049] Figure 4 The cell safety result diagram of the spot-lightening and mark-lightening whitening synergistic composition prepared in Example 5 of the present invention, the spot-lightening and mark-lightening whitening synergistic composition prepared in Comparative Examples 1 and 2, and the free whitening composition prepared in Comparative Example 3;

[0050] Figure 5 This is a graph of the in vitro release behavior of the spot-lightening, mark-lightening and whitening synergistic composition prepared in Example 5 of the present invention;

[0051] Figure 6 This is a graph showing the results of the measurement of the cumulative penetration amount and the skin retention amount of the spot-lightening and whitening synergistic composition prepared in Example 5 of the present invention and the free whitening composition prepared in Comparative Example 3;

[0052] Figure 7 It is a laser confocal microscope section image of the spot-lightening and whitening synergistic composition prepared in Example 5 of the present invention and the free whitening composition prepared in Comparative Example 3;

[0053] Figure 8 This is a graph showing the test results of cell uptake behavior observed by laser confocal microscopy of the spot-lightening and whitening synergistic composition prepared in Example 5 of the present invention and the free whitening composition prepared in Comparative Example 3;

[0054] Fig. 9 This is a test result diagram of the cell uptake behavior detected by flow cytometry of the spot-lightening and whitening synergistic composition prepared in Example 5 of the present invention and the free whitening composition prepared in Comparative Example 3;

[0055] Fig.10 This is a graph showing the effect of the spot-lightening, scar-lightening and whitening synergistic composition prepared in Example 5 of the present invention on the uptake of B16F10 cells and HaCaT cells;

[0056] Fig.11 It is a graph showing the results of intracellular tyrosinase activity assay of the spot-lightening and mark-lightening whitening synergistic composition prepared in Examples 1, 2 and 5 of the present invention, the spot-lightening and mark-lightening whitening synergistic composition prepared in Comparative Examples 1 and 2, and the free whitening composition prepared in Comparative Example 3;

[0057] Fig.12 The results of the whitening and synergistic compositions for lightening spots and marks prepared in Examples 1, 2 and 5 of the present invention, the whitening and synergistic compositions for lightening spots and marks prepared in Comparative Examples 1 and 2, and the free whitening composition prepared in Comparative Example 3 on the production of cellular melanin are shown in the figure;

[0058] Fig.13 This is a graph showing the whitening efficacy test results of the spot-lightening and mark-lightening whitening synergistic composition prepared in Example 5 of the present invention;

[0059] Fig.14 The results of the whitening efficacy test on the 3D skin melanin model of the spot-lightening and mark-lightening whitening synergistic composition prepared in Example 5 of the present invention, the spot-lightening and mark-lightening whitening synergistic composition prepared in Comparative Examples 1 and 2, and the free whitening composition prepared in Comparative Example 3;

[0060] Fig.15 This is a graph showing the peeling test results of the spot-lightening and whitening synergistic composition prepared in Example 5 of the present invention and the free whitening composition prepared in Comparative Example 3. DETAILED DESCRIPTION

[0061] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0062] The invention provides a spot-lightening, mark-lightening, whitening and synergistic composition containing mandelic acid and having a targeted transdermal delivery function. The composition is formed by an inner water phase, an oil phase and an outer water phase, i.e., the inner water phase is wrapped by the oil phase, and the outer water phase is wrapped by the oil phase. The inner water phase comprises an alpha-MSH antagonist; the oil phase comprises phenethyl resorcinol, palmitoyl tetrapeptide-7, acetyl dipeptide-1 cetyl ester, an emulsifier, neutral phospholipids and oils; the outer water phase comprises a keratin exfoliant and a polyglycerol ester emulsifier; and the keratin exfoliant comprises mandelic acid.

[0063] In the present invention, the inner water phase includes an α-MSH antagonist; once human stratum corneum cells receive ultraviolet rays, they will release a large amount of α-MSH. Melanocyte stimulating hormone (α-MSH) is the main factor affecting melanogenesis. They can bind to the melanocortin-1 receptor (MCIR) on the surface of the melanocyte membrane, increase the activity of intracellular tyrosinase through signal transduction, and thus increase the synthesis of melanin by melanocytes. MC1R is highly expressed in melanocytes, so selecting a ligand that can specifically bind to MC1R, namely an α-MSH antagonist, will play a more critical role in inhibiting melanogenesis. In the present invention, the α-MSH antagonist is any α-MSH antagonist known to those skilled in the art, and there is no particular limitation. In the present invention, it is preferably one or more of nonapeptide-1, undecylenoyl phenylalanine and hexapeptide-2; wherein, nonapeptide-1, also known as whitening peptide, as a bionic peptide, has a very good match with the MC1 receptor on melanocytes, and can competitively bind to the receptor MC1R on the surface of melanocytes, inhibiting the effect of MSH (melanocyte-stimulating hormone), blocking the transmission of melanin signals, that is, effectively playing a role in blocking melanin and reducing melanin. The α-MSH antagonist can be combined with other small molecule peptides to form proteins through peptide bond binding and peptide chain folding, and is absorbed by the skin, making the skin brighter, reducing the formation of spots and pigmentation in the skin, and achieving the effects of whitening and lightening spots, fading acne marks, and brightening the skin tone; the mass of the α-MSH antagonist is preferably 0.01% to 1% of the mass of the spot-lightening and whitening synergistic composition; in some embodiments provided by the present invention, the mass of the α-MSH antagonist is specifically 0.02%, 1%, 0.01%, 0.03% or 0.015% of the mass of the spot-lightening and whitening synergistic composition.

[0064] In the present invention, the inner aqueous phase preferably also includes a first polyol; the first polyol can be used as an emulsifier to change the rigidity of the nanoemulsion, improve the emulsification stability of the oil phase, reduce the interfacial tension so that the nanoemulsion is formed spontaneously, and expand the formation area of ​​the nanoemulsion. In addition, the polyol has a transdermal promotion effect, which can promote the active substance to pass through the stratum corneum of the skin, and can also improve the solubility and water dispersibility of the poorly soluble active substance; the first polyol is preferably one or more of glycerol, propylene glycol, butylene glycol, 1,2-pentanediol, 1,2-hexanediol, 1,3-propylene glycol, dipropylene glycol, PEG-10 propylene glycol and polyethylene glycol-400; the mass of the first polyol is preferably 1% to 5% of the mass of the spot-lightening and whitening synergistic composition; in some embodiments provided by the present invention, the mass of the first polyol is specifically 3%, 5%, 1% or 4% of the mass of the spot-lightening and whitening synergistic composition.

[0065] According to the present invention, the oil phase comprises phenethyl resorcinol, palmitoyl tetrapeptide-7, acetyl dipeptide-1 cetyl ester, an emulsifier, neutral phospholipids and oils; the mass of the phenethyl resorcinol is preferably 1% to 10% of the mass of the spot-lightening and whitening synergistic composition; in some embodiments provided by the present invention, the mass of the phenethyl resorcinol is specifically 5%, 10%, 1%, 6% or 4% of the mass of the spot-lightening and whitening synergistic composition; phenethyl resorcinol (377) is derived from the natural whitening ingredient in the European red pine cones - silver pinus argenteus, and after chemical modification, a new type of highly effective whitening active substance is screened out. Phenylethyl resorcinol can effectively inhibit the activity of tyrosinase, and tyrosine is a rate-limiting enzyme in the production of melanin, and its inhibitory effect is 22 times that of the gold standard whitening ingredient kojic acid, thereby inhibiting the regeneration of melanin at the source, which is beneficial to the disappearance of melanin and achieves a whitening effect; the mass of the palmitoyl tetrapeptide-7 is preferably 0.01% to 1% of the mass of the spot-lightening and whitening synergistic composition; in some embodiments provided by the present invention, the mass of the palmitoyl tetrapeptide-7 is specifically 0.02%, 1%, 0.01%, 0.03% of the mass of the spot-lightening and whitening synergistic composition or 0.015%; Palmitoyl tetrapeptide-7 is a synthetic peptide composed of four amino acids, which can stimulate the production of laminin IV and V and type II collagen and reduce the production of inflammatory factor-interleukin (IL-6), reduce the loss of skin collagen and elastic fibers, eliminate inflammation, increase skin elasticity, avoid wrinkles, sagging and uneven skin tone, and thus better help relieve the residual inflammation in the acne area of ​​acne patients and prevent the occurrence of post-inflammatory pigmentation; the mass of the acetyl dipeptide-1 cetyl ester is preferably 0.01% to 0.1% of the mass of the spot-lightening and whitening synergistic composition. 1%; in some embodiments provided by the present invention, the mass of the acetyl dipeptide-1 cetyl ester is specifically 0.02%, 1%, 0.01%, 0.03% or 0.015% of the mass of the spot-lightening and whitening synergistic composition; acetyl dipeptide-1 cetyl ester can inhibit CGRP and SP (these two mediators can cause microvascular dilation and plasma extravasation), inhibit vasodilation, reduce the skin's neurological response to irritants, and improve skin tolerance. It can be used to soothe and repair sensitive skin on the face or body, and in the process of exploring the present invention, it was found that acetyl dipeptide-1 cetyl ester can inhibit CGRP and SP (these two mediators can cause microvascular dilation and plasma extravasation), inhibit vasodilation, reduce the skin's neurological response to irritants, and improve skin tolerance. It can be used to soothe and repair sensitive skin on the face or body. In the process of exploring the present invention, it was found that acetyl dipeptide -1 has a high inhibitory effect on inflammatory mediators, especially PGE2, and its inhibitory effect can reach 74%. Therefore, this neurosoothing peptide can not only help relieve the irritation caused by high concentrations of mandelic acid and phenylethyl resorcinol, but also help to reduce the residual inflammation in the acne area and prevent the formation of post-inflammatory pigmentation; the mass ratio of phenylethyl resorcinol, palmitoyl tetrapeptide-7 and acetyl dipeptide-1 cetyl ester is preferably (1-10): (0.01-0.5): (0.01-0.5), and more preferably 5: (0.01-0.5): (0.01-0.5); In some embodiments provided by the present invention, the mass ratio of phenethyl resorcinol, palmitoyl tetrapeptide-7 and acetyl dipeptide-1 cetyl ester is specifically 5:0.02:0.02, 10:1:1, 1:0.01:0.01, 6:0.03:0.03 or 4:0.15:0.15; the mass ratio of palmitoyl tetrapeptide-7 and acetyl dipeptide-1 cetyl ester is preferably 1:(0.5-2), more preferably 1:(0.8-1.5), more preferably 1:(0.8-1.2), and most preferably 1:1; the emulsifier is an emulsifier well known to those skilled in the art. , without special restrictions, the present invention is preferably octyl glucoside, arachidyl glucoside, polyglycerol-10 oleate, polyglycerol-10 myristate, polyglycerol-4 oleate, polyoxyethylene hydrogenated castor oil and polysorbate-80 One or more; in the embodiments provided by the present invention, PEG-40 hydrogenated castor oil is specifically used as an example for illustration; the mass of the emulsifier is preferably 3% to 7% of the mass of the spot-lightening and whitening synergistic composition; in some embodiments provided by the present invention, the mass of the emulsifier is specifically 5%, 7%, 3%, 6% or 4% of the mass of the spot-lightening and whitening synergistic composition; the The neutral phospholipids may be neutral phospholipids known to those skilled in the art without any particular limitation. In the present invention, it preferably includes but is not limited to one or more of lecithin, soybean lecithin, hydrogenated soybean lecithin, dimyristoylphosphatidylcholine, dioleoylphosphatidylcholine, phosphatidylethanolamine, dioleoylphosphatidylethanolamine, cephalin, and sphingomyelin; the mass of the neutral phospholipids is preferably 1% to 5% of the mass of the spot-lightening and whitening synergistic composition; in some embodiments provided by the present invention, the mass of the neutral phospholipids is specifically 3%, 5%, 1%, 4% or 2% of the mass of the spot-lightening and whitening synergistic composition; the oils and fats may be any one of the skilled in the art; The oils and fats known to technicians are not particularly limited. In the present invention, it preferably includes but is not limited to one or more of caprylic / capric triglyceride, palmitic triglyceride, isopropyl palmitate, tri(ethylhexanoin)glyceride, isopropyl myristate, ethylhexyl cocoate, ethylhexyl palmitate, isoamyl laurate, squalane, olive oil, soybean oil and jojoba seed oil; the mass of the oil and fat is preferably 1% to 5% of the mass of the spot-lightening and whitening synergistic composition; in some embodiments provided by the present invention, the mass of the oil and fat is specifically 3%, 5%, 1%, 4% or 2% of the mass of the spot-lightening and whitening synergistic composition. .

[0066] According to the present invention, the external aqueous phase includes a keratin exfoliant and a polyglycerol ester emulsifier; the keratin exfoliant can be a keratin exfoliant known to those skilled in the art, and there is no special limitation. In addition to mandelic acid, the present invention may also include other components, preferably including but not limited to salicylic acid and / or capryloyl salicylic acid; mandelic acid, also known as mandelic acid, is a fruit acid belonging to an α-hydroxy acid and is the only one with lipophilic effect. In 1999, American dermatologist Taylor conducted a clinical application study of mandelic acid on 1,100 patients for more than three years and pointed out that mandelic acid has a good effect on inhibiting and improving pigmentation, treating inflammatory acne and photoaging, and is relatively mild and is not easy to produce post-inflammatory pigmentation (compared with glycolic acid, or other medicinal ingredients, such as acne-retinoids, whitening drugs-hydroquinone). Mandelic acid combines with calcium ions in desmosomes, thereby destroying the integrity of desmosome proteins, reducing the connectivity between stratum corneum, thereby helping the stratum corneum to fall off, accelerating the metabolism of the stratum corneum, and allowing the pigmentation deposited in the stratum corneum to fall off, achieving a whitening effect. The mass of the keratin exfoliant is preferably 1% to 10% of the mass of the nanocomposition; in some embodiments provided by the present invention, the mass of the keratin exfoliant is specifically 1%, 7%, 10%, 8% or 6% of the mass of the blemish-lightening and whitening synergistic composition; the polyglycerol ester emulsifier can be a polyglycerol ester emulsifier well known to those skilled in the art, and there is no special restriction. In the present invention, it preferably includes but is not limited to one or more of polyglycerol-10 myristate, polyglycerol-10 oleate, polyglycerol-10 dipalmitate and polyglycerol-10 diisostearate; the mass of the polyglycerol ester emulsifier is preferably 1% to 5% of the mass of the nanocomposition; in some embodiments provided by the present invention, the mass of the polyglycerol ester emulsifier is specifically 3%, 5%, 1%, 4% or 2% of the mass of the blemish-lightening and whitening synergistic composition.

[0067] According to the present invention, the external aqueous phase preferably also includes a second polyol; the second polyol is preferably one or more of glycerol, propylene glycol, butylene glycol, 1,2-pentanediol, 1,2-hexanediol, 1,3-propanediol, dipropylene glycol, PEG-10 propylene glycol and polyethylene glycol-400; the mass of the second polyol is preferably 10% to 20% of the mass of the spot-lightening and whitening synergistic composition; in some embodiments provided by the present invention, the mass of the second polyol is specifically 15%, 20%, 18%, 10% or 12% of the mass of the spot-lightening and whitening synergistic composition.

[0068] According to the present invention, the inner aqueous phase and the outer aqueous phase also include water, and the amount of water in the two makes the total amount of the spot-lightening and whitening synergistic composition 100%; the mass of water in the inner aqueous phase is preferably 5% to 20% of the total amount of water in the spot-lightening and whitening synergistic composition, more preferably 8% to 15%, and even more preferably 10% to 15%.

[0069] The outermost layer of the spot-lightening and mark-lightening whitening synergistic composition provided by the present invention is an exfoliating active ingredient containing a high concentration of mandelic acid, which is released first and can help to quickly lighten the pigmentation already formed on the epidermis, that is, play an accelerating role in lightening the black color; the inner layer contains a high concentration of phenylethyl resorcinol and other whitening active ingredients, which can penetrate into the target site of the melanocytes in the basal layer, and effectively play the role of blocking blackening and suppressing blackness at the source; the skin care concept of highly consistent and precise release is achieved through the inner water phase, the oil phase and the outer water phase, and can help to more efficiently and specifically overcome the pigmentation of people with acne; in addition, dual anti-allergic peptides are added to the oil phase, which can help to reduce the inflammation remaining in acne skin, prevent inflammation-induced pigmentation, and can also help to reduce the irritation caused by high concentrations of mandelic acid and phenylethyl resorcinol, reduce the secondary stimulation brought to people with acne skin, and thus help them to better lighten black acne marks.

[0070] The present invention also provides a method for preparing a stigma-lightening, scar-lightening and whitening synergistic composition containing mandelic acid and having a targeted transdermal delivery function, comprising the following steps: S1) mixing an α-MSH antagonist with water to obtain an inner water phase; mixing phenylethyl resorcinol, palmitoyl tetrapeptide-7, acetyl dipeptide-1 cetyl ester, an emulsifier, a neutral phospholipid and oil to obtain an oil phase; mixing a keratin exfoliant, a polyglycerol ester emulsifier and water to obtain an outer water phase; S2) dripping the inner water phase into the oil phase and mixing to obtain an oil-in-water system; S3) dripping the oil-in-water system into the outer water phase and mixing to obtain a water-in-oil-in-water emulsion; S4) subjecting the water-in-oil-in-water emulsion to micronization treatment to obtain a micron-sized dispersion; S5) subjecting the micron-sized dispersion to nanometerization treatment to obtain a stigma-lightening, scar-lightening and whitening synergistic composition containing mandelic acid and having a targeted transdermal delivery function.

[0071] Among them, the present invention has no special restrictions on the sources of all raw materials, and they can be commercially available; the types and contents of the α-MSH antagonist, phenethyl resorcinol, palmitoyl tetrapeptide-7, acetyl dipeptide-1 cetyl ester, emulsifier, neutral phospholipids, oils, keratin peeling agents and polyglycerol ester emulsifier are the same as described above and will not be repeated here.

[0072] An α-MSH antagonist is mixed with water to obtain an inner water phase; the mass of the water is 5% to 20% of the water content in the spot-lightening and scar-lightening whitening and enhancing composition, more preferably 8% to 15%, and even more preferably 10% to 15%; in the present invention, a first polyol is preferably added; the type and content of the first polyol are the same as described above and will not be repeated here; the mixing temperature is preferably 40°C to 70°C, more preferably 40°C to 60°C, and even more preferably 40°C to 50°C.

[0073] Phenylethyl resorcinol, palmitoyl tetrapeptide-7, acetyl dipeptide-1 cetyl ester, an emulsifier, a neutral phospholipid and oil are mixed to obtain an oil phase; the mixing temperature is preferably 40°C to 70°C, more preferably 40°C to 60°C, and even more preferably 40°C to 50°C.

[0074] The keratin exfoliant, the polyglycerol ester emulsifier and water are mixed to obtain an external aqueous phase; the mixing temperature is preferably 40°C to 70°C, more preferably 40°C to 60°C, and even more preferably 40°C to 50°C.

[0075] The inner aqueous phase is added dropwise to the oil phase and mixed to obtain an oil-in-water system; the dropping speed is preferably 1 to 5 drops / s, more preferably 1 to 3 drops / s, and more preferably 1 to 2 drops / s; the mixing rotation speed is preferably 10 to 60 rpm, more preferably 10 to 40 rpm, more preferably 10 to 30 rpm, and most preferably 15 to 20 rpm; the mixing temperature is preferably 40°C to 70°C, more preferably 40°C to 60°C, and more preferably 40°C to 50°C.

[0076] The water-in-oil system is added dropwise to the external aqueous phase and mixed to obtain a water-in-oil-in-water emulsion; the dropping speed is preferably 1 to 5 drops / s, more preferably 1 to 3 drops / s, and more preferably 1 to 2 drops / s; the mixing rotation speed is preferably 10 to 60 rpm, more preferably 20 to 50 rpm, more preferably 20 to 40 rpm, and most preferably 30 rpm; the mixing temperature is preferably 40°C to 70°C, more preferably 40°C to 60°C, and more preferably 40°C to 50°C.

[0077] The water-in-oil-in-water emulsion is micronized to obtain a micron-sized dispersion; the micronization is preferably high-speed shearing; the rotation speed of the high-speed shearing is preferably 4000-10000rpm, more preferably 6000-10000rpm, and more preferably 8000-10000rpm; the time of high-speed shearing is preferably 1-10min, more preferably 1-6min, more preferably 1-4min, and most preferably 1-2min.

[0078] The micron-scale dispersion is subjected to nano-treatment to obtain a spot-lightening, scar-lightening, whitening and synergistic composition containing mandelic acid and having a targeted transdermal delivery function; the nano-treatment is preferably a high-pressure homogenization treatment or a high-speed microfluidization treatment; the pressure of the high-pressure homogenization treatment is preferably 300-1600 bar, more preferably 500-1600 bar, more preferably 800-1600 bar, more preferably 1000-1600 bar, more preferably 1200-1600 bar, and most preferably 1500 bar; the number of cycles of the high-pressure homogenization treatment is preferably 1-10 times, more preferably 1-8 times, more preferably 2-6 times, and most preferably 2-4 times; the pressure of the high-speed microfluidization treatment is preferably 5000-16000 psi; the number of cycles of the high-pressure microfluidization treatment is preferably 1-10 times, more preferably 1-8 times, more preferably 2-6 times, and most preferably 2-4 times.

[0079] The present invention also provides a cosmetic comprising the above-mentioned blemish-lightening, mark-lightening and whitening synergistic composition containing mandelic acid and having a targeted transdermal delivery function.

[0080] In the present invention, the mass of the spot-lightening, mark-removing, whitening and synergistic composition containing mandelic acid and having a targeted transdermal delivery function is preferably 0.01% to 10% of the mass of the cosmetic, more preferably 0.01% to 8%, and even more preferably 0.01% to 5%; the mass concentration of the spot-lightening, mark-removing, whitening and synergistic composition containing mandelic acid and having a targeted transdermal delivery function in the cosmetic can be any point value within the above range. Specifically, in some embodiments provided by the present invention, the mass of the spot-lightening, mark-removing, whitening and synergistic composition containing mandelic acid and having a targeted transdermal delivery function can be 0.01%, 0.04%, 0.1%, 0.2%, 0.5%, 1.5%, 2%, 3%, 5%, 8% or 10% of the mass of the cosmetic.

[0081] In the present invention, the cosmetics are daily chemicals applied to the skin surface that are well known to those skilled in the art, and there are no special restrictions. In the present invention, the cosmetics are preferably cosmetics that have the effects of whitening and fading acne marks.

[0082] In the present invention, the cosmetics are preferably leave-on skin care products such as essence, lotion, face cream, body lotion, etc.

[0083] According to the present invention, the essence preferably also includes a moisturizer; the mass of the moisturizer is preferably 1% to 10% of the mass of the essence, more preferably 3% to 8%, more preferably 5% to 8%, and most preferably 6% to 7%; the moisturizer can be a moisturizer well known to those skilled in the art, without any special restrictions, and the present invention preferably includes but is not limited to one or more of butylene glycol, 1,2-pentanediol, dipropylene glycol, trehalose, panthenol, diglycerin, β-glucan, glycerol, propylene glycol, 1,3-propylene glycol, butylene glycol, hexylene glycol, sodium hyaluronate, glyceryl polyether-26 and amino acid moisturizer.

[0084] According to the present invention, the essence preferably further comprises a chelating agent; the mass of the chelating agent is preferably 0.01% to 0.1% of the mass of the essence, more preferably 0.02% to 0.08%, and even more preferably 0.03% to 0.05%; the chelating agent is any chelating agent well known to those skilled in the art, without any particular limitation, and the present invention preferably comprises but is not limited to one or more of tetrasodium EDTA, disodium EDTA, EDTA and phytic acid.

[0085] According to the present invention, the essence preferably also includes an emollient; the mass of the lubricant is preferably 1% to 10% of the mass of the essence, more preferably 2% to 8%, more preferably 2% to 6%, and most preferably 3% to 5%; the lubricant can be a lubricant well known to those skilled in the art, without any special restrictions, and preferably includes but is not limited to one or more of dicaprylyl carbonate, dicaprylyl ether, coconut oil alcohol-caprylate / caprate, octyldodecanol, squalane, glyceryl tri(ethylhexanoate) and polydimethylsiloxane.

[0086] According to the present invention, the essence preferably further includes a thickener; the mass of the thickener is preferably 0.01% to 1% of the mass of the essence, more preferably 0.01% to 0.5%, more preferably 0.01% to 0.3%, more preferably 0.05% to 0.1%, and most preferably 0.08%; the thickener can be a thickener well known to those skilled in the art without any special restrictions, and the present invention preferably includes but is not limited to one or more of the carbomer series, acrylic copolymer series, xanthan gum, SepigelEG, SIMULGELNS, Aristoflex avc and Aristoflex HMB.

[0087] According to the present invention, the essence preferably further includes an emulsifier; the mass of the emulsifier is preferably 0.5% to 3% of the mass of the essence, more preferably 0.8% to 2.5%, more preferably 1% to 2%, and most preferably 1.5% to 2%; the emulsifier is an emulsifier well known to those skilled in the art, and there is no special limitation. The present invention preferably includes but is not limited to cetyl alcohol, coconut oil glucoside, cetearyl glucoside (and) cetearyl alcohol, glyceryl stearate (and) PEG-100 stearate, arachidyl alcohol (and) behenyl alcohol (and ) Arachidyl Glucoside, PEG-10 Dimethicone, Polysorbate-20, Glyceryl Stearate, PEG-100 Stearate, Steareth-21 Sorbitan Stearate, Potassium Cetyl Phosphate, Sodium Methyl Cocoyl Taurate, Methyl Glucose Sesquistearate, C14-22 Alcohol / C12-20 Alkyl Glucoside, Sodium Acrylate / Sodium Acryloyldimethyl Taurate Copolymer (and) Isohexadecane (and) Polysorbate-80, Ammonium Acryloyldimethyl Taurate / VP Copolymer, or any one or a combination of at least two thereof.

[0088] According to the present invention, the essence preferably further includes a natural preservative; the mass of the natural preservative is preferably 0.1% to 0.5% of the mass of the essence, more preferably 0.2% to 0.4%, and even more preferably 0.3%; the natural preservative is a natural preservative well known to those skilled in the art, and there is no particular limitation. In the present invention, it preferably includes but is not limited to p-hydroxyacetophenone.

[0089] According to the present invention, the essence preferably further includes a pH adjuster; the mass of the pH adjuster is preferably 0.01% to 0.1% of the mass of the essence, more preferably 0.01% to 0.05%; the pH adjuster can be a pH adjuster well known to those skilled in the art, without any special restrictions, and preferably includes but is not limited to aminomethyl propanol in the present invention.

[0090] The cosmetic provided by the present invention comprises a spot-lightening, mark-lightening and whitening synergistic composition containing mandelic acid and having a targeted transdermal delivery function, and can be used for treating skin problems related to pigmentation.

[0091] To further illustrate the present invention, the following describes in detail a spot-lightening, scar-lightening, whitening and synergistic composition containing mandelic acid with targeted transdermal delivery function, a preparation method thereof and applications thereof in conjunction with embodiments.

[0092] The reagents used in the following examples are all commercially available; the lecithin used in the examples is from Shanghai Taiwei Pharmaceutical Co., Ltd.; the PBS solution used in the examples is from Gibco, with a pH value of 7.4; the lipase used in the examples is from Shanghai Aladdin Biochemical Technology Co., Ltd., CAS: 9001-62-1.

[0093] To explore the anti-allergic effect of dual anti-allergic soothing peptides. In order to eliminate or reduce the irritation of phenylethyl resorcinol, many anti-allergic agents were selected, and it was found that palmitoyl tetrapeptide-7 and acetyl dipeptide-1 cetyl ester had better effects, especially when palmitoyl tetrapeptide-7 and acetyl dipeptide-1 cetyl ester were used together. The relevant test experiments and results are as follows:

[0094] 1. Preparation of free whitening composition

[0095] (1) In terms of mass percentage, 0.02% nonapeptide-1, 3% 1,2-pentanediol, 5% phenylethyl resorcinol, 0.04% palmitoyl tetrapeptide-7, 5% PEG-40 hydrogenated castor oil, 3% lecithin, 3% caprylic / capric triglyceride, 7% mandelic acid, 15% 1,3-propylene glycol, and 3% polyglyceryl-10 diisostearate were stirred and fully mixed in a 40° C. water bath to obtain a free whitening composition 1.

[0096] (2) In terms of mass percentage, 0.02% nonapeptide-1, 3% 1,2-pentanediol, 5% phenylethyl resorcinol, 0.04% acetyl dipeptide-1 cetyl ester, 5% PEG-40 hydrogenated castor oil, 3% lecithin, 3% caprylic / capric triglyceride, 7% mandelic acid, 15% 1,3-propylene glycol, and 3% polyglyceryl-10 diisostearate were stirred and mixed thoroughly in a 40° C. water bath to obtain a free whitening composition 2.

[0097] (3) In terms of mass percentage, 0.02% nonapeptide-1, 3% 1,2-pentanediol, 5% phenylethyl resorcinol, 0.02% palmitoyl tetrapeptide-7, 0.02% acetyl dipeptide-1 cetyl ester, 5% PEG-40 hydrogenated castor oil, 3% lecithin, 3% caprylic / capric triglyceride, 7% mandelic acid, 15% 1,3-propylene glycol, and 3% polyglyceryl-10 diisostearate were stirred and mixed thoroughly in a water bath at 40° C. to obtain a free whitening composition 3.

[0098] 2. Patch test

[0099] 31 subjects were selected in the experiment and their reactions were recorded. A 10% free whitening composition patch cream filter paper was placed in the patch tester, and the normal hole was used as a blank control. The sample and the blank control were both applied to the curved side of the subject's forearm, and gently pressed with the palm to evenly apply it to the skin for 24 hours. After removing the patch tester, the skin reaction was observed after an interval of 30 minutes after the indentation disappeared. The skin reaction was observed again 24 hours and 48 hours after the patch tester was removed, and the results were shown in Table 1. The formula of the patch cream is as follows: by mass percentage, 2.0% PEC-10 polydimethylsiloxane, 1.0% sucrose stearate, 1.0% stearyl alcohol, 4.5% monostearate glyceryl enzyme, 1.0% cetostearyl alcohol, and 3.0% jojoba oil are melted in a 75°C water bath to obtain an oil phase; 5.0% glycerol, 5.0% propylene glycol, 0.3% triethanolamine, 0.2% carbomer 2020 and 67.0% purified water are dissolved in a 75°C water bath to obtain an aqueous phase; the oil phase and the aqueous phase are stirred and mixed, and emulsified, and the temperature is continuously stirred to 40°C, and then 10% free whitening composition is added and stirred evenly to obtain a patch cream containing 10% high-concentration free whitening composition for use in patches.

[0100] Table 1 Human skin occlusive patch test results

[0101]

[0102] The results in Table 1 show that the combination of palmitoyl tetrapeptide-7 and acetyl dipeptide-1 cetyl ester can synergistically enhance the anti-allergic effect of phenylethyl resorcinol and produce better effects. Therefore, palmitoyl tetrapeptide-7 and acetyl dipeptide-1 cetyl ester are selected as anti-allergic agents to prepare the spot-lightening and whitening synergistic composition.

[0103] Example 1

[0104] (1) Dissolve 1% nonapeptide-1 and 5% 1,2-pentanediol in part of water at 40°C in a water bath to obtain phase A (internal aqueous phase). The water used in this step is 10% of the total water used.

[0105] (2) 10% phenylethyl resorcinol (377), 1% palmitoyl tetrapeptide-7, 1% acetyl dipeptide-1 cetyl ester, 7% PEG-40 hydrogenated castor oil, 5% lecithin, and 5% caprylic / capric triglyceride were stirred and dissolved in a 40°C water bath to obtain phase B (oil phase).

[0106] (3) Add phase A to phase B at a rate of 1 drop / second in a 40°C water bath. During the addition, the stirring rate is controlled at 15 rpm. After mixing, phase C (water-in-oil) is obtained.

[0107] (4) 10% mandelic acid, 20% 1,3-propylene glycol, and 5% polyglyceryl-10 diisostearate were dissolved in the remaining water at 40° C. to obtain phase D (external aqueous phase).

[0108] (5) In a 40°C water bath, phase C was added dropwise to phase D at a rate of 2 drops / second. During the addition, the stirring rate was controlled at 30 rpm. After mixing, a water-in-oil-in-water system was obtained.

[0109] (6) The water-in-oil-in-water system was high-speed sheared and emulsified at 10,000 rpm for 1 min to prepare a micron-sized dispersion.

[0110] (7) The micron-sized dispersion is subjected to high-pressure homogenization treatment at 1500 bar, and the process is repeated twice to obtain a spot-lightening and whitening synergistic composition.

[0111] Example 2

[0112] (1) 0.01% nonapeptide-1 and 1% 1,2-pentanediol were dissolved in part of water at 40°C in a water bath to obtain phase A (internal aqueous phase). The water used in this step accounted for 10% of the total water used.

[0113] (2) 1% phenylethyl resorcinol (377), 0.01% palmitoyl tetrapeptide-7, 0.01% acetyl dipeptide-1 cetyl ester, 3% PEG-40 hydrogenated castor oil, 1% lecithin, and 1% caprylic / capric triglyceride were stirred and dissolved in a 40°C water bath to obtain phase B (oil phase).

[0114] (3) Add phase A to phase B at a rate of 1 drop / second in a 40°C water bath. During the addition, the stirring rate is controlled at 15 rpm. After mixing, phase C (water-in-oil) is obtained.

[0115] (4) 1% mandelic acid, 10% 1,3-propylene glycol, and 1% polyglyceryl-10 diisostearate were dissolved in the remaining water at 40° C. to obtain phase D (external aqueous phase).

[0116] (5) In a 40°C water bath, phase C was added dropwise to phase D at a rate of 2 drops / second. During the addition, the stirring rate was controlled at 30 rpm. After mixing, a water-in-oil-in-water system was obtained.

[0117] (6) The water-in-oil-in-water system was high-speed sheared and emulsified at 10,000 rpm for 1 min to prepare a micron-sized dispersion.

[0118] (7) The micron-sized dispersion is subjected to high-pressure homogenization treatment at 1500 bar, and the process is repeated twice to obtain a spot-lightening and whitening synergistic composition.

[0119] Example 3

[0120] (1) 0.03% nonapeptide-1 and 4% 1,2-pentanediol were dissolved in part of water at 40°C in a water bath to obtain phase A (internal aqueous phase). The water used in this step accounted for 10% of the total water used.

[0121] (2) 6% phenylethyl resorcinol (377), 0.03% palmitoyl tetrapeptide-7, 0.03% acetyl dipeptide-1 cetyl ester, 6% PEG-40 hydrogenated castor oil, 4% lecithin, and 4% caprylic / capric triglyceride were stirred and dissolved in a 40°C water bath to obtain phase B (oil phase).

[0122] (3) Add phase A to phase B at a rate of 1 drop / second in a 40°C water bath. During the addition, the stirring rate is controlled at 15 rpm. After mixing, phase C (water-in-oil) is obtained.

[0123] (4) 8% of mandelic acid, 18% of 1,3-propylene glycol, and 4% of polyglyceryl-10 diisostearate were dissolved in the remaining water at 40° C. to obtain phase D (external aqueous phase).

[0124] (5) In a 40°C water bath, phase C was added dropwise to phase D at a rate of 2 drops / second. During the addition, the stirring rate was controlled at 30 rpm. After mixing, a water-in-oil-in-water system was obtained.

[0125] (6) The water-in-oil-in-water system was high-speed sheared and emulsified at 10,000 rpm for 1 min to prepare a micron-sized dispersion.

[0126] (7) The micron-sized dispersion is subjected to high-pressure homogenization treatment at 1500 bar, and the process is repeated twice to obtain a spot-lightening and whitening synergistic composition.

[0127] Example 4

[0128] (1) 0.015% nonapeptide-1 and 2% 1,2-pentanediol were dissolved in part of water at 40°C in a water bath to obtain phase A (internal aqueous phase). The water used in this step accounted for 10% of the total water used.

[0129] (2) 4% phenylethyl resorcinol (377), 0.015% palmitoyl tetrapeptide-7, 0.015% acetyl dipeptide-1 cetyl ester, 4% PEG-40 hydrogenated castor oil, 2% lecithin, and 2% caprylic / capric triglyceride were stirred and dissolved in a 40°C water bath to obtain phase B (oil phase).

[0130] (3) Add phase A to phase B at a rate of 1 drop / second in a 40°C water bath. During the addition, the stirring rate is controlled at 15 rpm. After mixing, phase C (water-in-oil) is obtained.

[0131] (4) 6% mandelic acid, 12% 1,3-propylene glycol, and 2% polyglyceryl-10 diisostearate were dissolved in the remaining water at 40° C. to obtain phase D (external aqueous phase).

[0132] (5) In a 40°C water bath, phase C was added dropwise to phase D at a rate of 2 drops / second. During the addition, the stirring rate was controlled at 30 rpm. After mixing, a water-in-oil-in-water system was obtained.

[0133] (6) The water-in-oil-in-water system was high-speed sheared and emulsified at 10,000 rpm for 1 min to prepare a micron-sized dispersion.

[0134] (7) The micron-sized dispersion is subjected to high-pressure homogenization treatment at 1500 bar, and the process is repeated twice to obtain a spot-lightening and whitening synergistic composition.

[0135] Example 5

[0136] (1) 0.02% nonapeptide-1 and 3% 1,2-pentanediol were dissolved in part of water at 40°C in a water bath to obtain phase A (internal aqueous phase). The water used in this step accounted for 10% of the total water used.

[0137] (2) 5% phenylethyl resorcinol (377), 0.02% palmitoyl tetrapeptide-7, 0.02% acetyl dipeptide-1 cetyl ester, 5% PEG-40 hydrogenated castor oil, 3% lecithin, and 3% caprylic / capric triglyceride were stirred and dissolved in a 40°C water bath to obtain phase B (oil phase).

[0138] (3) Add phase A to phase B at a rate of 1 drop / second in a 40°C water bath. During the addition, the stirring rate is controlled at 15 rpm. After mixing, phase C (water-in-oil) is obtained.

[0139] (4) 7% mandelic acid, 15% 1,3-propylene glycol, and 3% polyglyceryl-10 diisostearate were dissolved in the remaining water at 40° C. to obtain phase D (external aqueous phase).

[0140] (5) In a 40°C water bath, phase C was added dropwise to phase D at a rate of 2 drops / second. During the addition, the stirring rate was controlled at 30 rpm. After mixing, a water-in-oil-in-water system was obtained.

[0141] (6) The water-in-oil-in-water system was high-speed sheared and emulsified at 10,000 rpm for 1 min to prepare a micron-sized dispersion.

[0142] (7) The micron-sized dispersion is subjected to high-pressure homogenization treatment at 1500 bar, and the process is repeated twice to obtain a spot-lightening and whitening synergistic composition.

[0143] In the spot-lightening and mark-lightening whitening and synergistic composition, mandelic acid is wrapped in an outer water phase, phenylethyl resorcinol, palmitoyl tetrapeptide-7 and acetyl dipeptide-1 cetyl ester are wrapped in an intermediate oil phase, and nonapeptide-1 is wrapped in an inner water phase.

[0144] Comparative Example 1

[0145] (1) 7% mandelic acid, 5% phenethyl resorcinol, 5% PEG-40 hydrogenated castor oil, 3% lecithin, 15% 1,3-propylene glycol, 3% polyglyceryl-10 diisostearate, and 3% caprylic / capric triglyceride were mixed and dissolved in a 40° C. water bath to obtain phase A (oil phase).

[0146] (2) 0.02% nonapeptide-1, 0.02% palmitoyl tetrapeptide-7, 0.02% acetyl dipeptide-1 cetyl ester, and 3% 1,2-pentanediol were added to the remaining water and heated in a water bath at 40° C. to dissolve to obtain phase B (aqueous phase).

[0147] (3) Add phase A to phase B at a rate of 2 drops / second in a 40°C water bath. During the addition, the stirring rate is controlled at 30 rpm. After mixing, phase C (oil-in-water) is obtained.

[0148] (4) Phase C was emulsified at high speed shear at 10,000 rpm for 1 min to prepare a micron-sized dispersion.

[0149] (5) The micron-sized dispersion is subjected to high-pressure homogenization treatment at 1500 bar, and the process is repeated twice to obtain a spot-lightening and whitening synergistic composition.

[0150] The contents of the components in this comparative example are the same as those in Example 5, with mandelic acid and phenethyl resorcinol being wrapped in the inner oil phase, and nonapeptide-1, palmitoyl tetrapeptide-7, and acetyl dipeptide-1 cetyl ester being wrapped in the outer water phase.

[0151] Comparative Example 2

[0152] (1) 0.02% nonapeptide-1, 7% mandelic acid, 15% 1,3-propylene glycol, and 3% polyglycerol-10 diisostearate were dissolved in water at 40° C. to obtain phase A (aqueous phase).

[0153] (2) 5% phenylethyl resorcinol, 0.02% palmitoyl tetrapeptide-7, 0.02% acetyl dipeptide-1 cetyl ester, 5% PEG-40 hydrogenated castor oil, 3% lecithin, 3% caprylic / capric triglyceride, and 3% 1,2-pentanediol were stirred and dissolved in a 40° C. water bath to obtain phase B (oil phase).

[0154] (3) Add phase B to phase A at a rate of 2 drops / second in a 40°C water bath. During the addition, the stirring rate is controlled at 30 rpm. After mixing, phase C (oil-in-water) is obtained.

[0155] (4) Phase C was emulsified at high speed shear at 10,000 rpm for 1 min to prepare a micron-sized dispersion.

[0156] (5) The micron-sized dispersion is subjected to high-pressure homogenization treatment at 1500 bar, and the process is repeated twice to obtain a spot-lightening and whitening synergistic composition.

[0157] The contents of the components in this comparative example are the same as those in Example 5, with mandelic acid and nonapeptide-1 being encapsulated in the outer water phase, and phenylethyl resorcinol, palmitoyl tetrapeptide-7, and acetyl dipeptide-1 cetyl ester being encapsulated in the inner oil phase.

[0158] The whitening and synergistic composition for lightening and whitening obtained in the above-mentioned examples 1 to 5 and the whitening and synergistic composition for lightening and whitening obtained in comparative examples 1 to 2 are light brown to light brown transparent liquids in appearance, with an average particle size of 10.0 to 100.0 nm, and PDI ≤ 0.400. The whitening and synergistic composition for lightening and whitening obtained in examples 1 to 5 and the whitening and synergistic composition for lightening and whitening obtained in comparative examples 1 to 2 are placed in a sealed container, and placed at room temperature, 4°C, and 45°C for 3 months, respectively, or subjected to a freeze-thaw experiment (the sample is placed in a sealed container, placed at -20°C for 48 hours, and then placed at 45°C for 48 hours, and cycled twice), and no stratification or precipitation occurs, and the particle size does not change significantly, indicating that the obtained whitening and synergistic composition for lightening and whitening has good stability.

[0159] Comparative Example 3

[0160] 0.02% nonapeptide-1, 3% 1,2-pentanediol, 5% phenylethyl resorcinol, 0.02% palmitoyl tetrapeptide-7, 0.02% acetyl dipeptide-1 cetyl ester, 5% PEG-40 hydrogenated castor oil, 3% lecithin, 3% caprylic / capric triglyceride, 7% mandelic acid, 15% 1,3-propylene glycol, and 3% polyglyceryl-10 diisostearate were stirred and fully mixed under 40° C. water bath conditions to obtain a free whitening composition. The content of the ingredients in this comparative example is the same as that in Example 5.

[0161] Comparative Example 4

[0162] The preparation method and formula are the same as those in Example 5, except that 0.02% of palmitoyl tetrapeptide-7 and 0.02% of acetyl dipeptide-1 cetyl ester are replaced with 0.04% of palmitoyl tetrapeptide-7.

[0163] Comparative Example 5

[0164] The preparation method and formula are the same as those of Example 5, except that 0.02% of palmitoyl tetrapeptide-7 and 0.02% of acetyl dipeptide-1 cetyl ester are replaced with 0.04% of acetyl dipeptide-1 cetyl ester.

[0165] Comparative Example 6

[0166] The preparation method and formula are the same as those in Example 5, except that 0.02% of palmitoyl tetrapeptide-7 and 0.02% of acetyl dipeptide-1 cetyl ester are replaced with 0.04% of palmitoyl tripeptide-8.

[0167] Comparative Example 7

[0168] The preparation method and formula are the same as those in Example 5, except that 0.02% of palmitoyl tetrapeptide-7 and 0.02% of acetyl dipeptide-1 cetyl ester are replaced with 0.04% of acetyl tetrapeptide-15.

[0169] Comparative Example 8

[0170] The preparation method and formula are the same as those in Example 5, except that 0.02% of palmitoyl tetrapeptide-7 and 0.02% of acetyl dipeptide-1 cetyl ester are replaced with 0.02% of acetyl tetrapeptide-15 and 0.02% of palmitoyl tripeptide-8.

[0171] Comparative Example 9

[0172] The preparation method and formula are the same as those of Example 5, except that the polyglycerol-10 diisostearate in step (4) is replaced by polyoxyethylene 40 hydrogenated castor oil.

[0173] Comparative Example 10

[0174] The preparation method and formula are the same as those of Example 5, except that polyglyceryl-10 diisostearate in step (4) is replaced by cocoyl glucoside.

[0175] Test Example 1 Double-layer packaging system and in vitro release behavior study

[0176] The microscopic morphology of the spot-lightening, mark-lightening, whitening and synergistic composition prepared in Example 5 was observed by transmission electron microscopy. Figure 1 The double-layer structure can be clearly seen through the electron microscope image.

[0177] Secondly, the dialysis bag method was used to study the difference in in vitro release behavior of the spot-lightening and whitening synergistic composition prepared in Example 5, the spot-lightening and whitening synergistic composition prepared in Comparative Examples 1, 9 and 10, and the free whitening composition prepared in Comparative Example 3. The dialysis bag (molecular weight cutoff of 3500Da) was boiled with ultrapure water for 5 minutes before use and soaked in 50% ethanol solution overnight. 2g of the dispersion of different spot-lightening and whitening synergistic compositions or free whitening compositions was placed in the dialysis bag, sealed at both ends with dialysis bag clips, and placed in a blue-mouthed bottle containing 80mL of release medium, and the release medium was 20% propylene glycol PBS solution (PH 7.4). The three groups of samples were shaken in a shaker at 37°C and 100rpm for 12h, and 1mL was sampled at 1, 2, 4, 6, 8, 10 and 12h, respectively, and the same volume of release medium was immediately supplemented. The concentrations of phenylethyl resorcinol (377) and mandelic acid in the samples taken at different time points were determined by HPLC, and the cumulative release percentages of phenylethyl resorcinol (377) and mandelic acid were calculated. The results are shown in Figure 2-3 .

[0178] Depend on Figure 2 It can be seen that compared with the phenethyl resorcinol (377) in Comparative Example 3, the release rate of phenethyl toluene diol in the spot-lightening and whitening synergistic composition prepared in Example 5, Comparative Example 1, Comparative Example 9 and Comparative Example 10 is significantly slowed down, showing obvious sustained-release characteristics. Compared with the mandelic acid in Comparative Example 3, the release rate of mandelic acid in the spot-lightening and whitening synergistic composition prepared in Example 5 and Comparative Example 1 is slowed down, showing significant sustained-release characteristics. The mandelic acid in Comparative Example 1 is in the inner oil phase, i.e., the innermost layer, and the mandelic acid in Example 5 is in the outer water phase, i.e., the outermost layer. Compared with Example 5, the release rate of mandelic acid in the spot-lightening and whitening synergistic composition prepared in Comparative Example 1 is more significantly slowed down. Compared with the phenethyl resorcinol (377) in Example 5, the release rate of phenethyl resorcinol (377) in the spot-lightening and whitening synergistic composition prepared in Comparative Examples 9 and Comparative Examples 10 is faster. Compared with the mandelic acid in Example 5, the release rate of mandelic acid in the spot-lightening and whitening synergistic compositions prepared in Comparative Examples 9 and 10 is faster. This indicates that when polyoxyethylene 40 hydrogenated castor oil and coconut glucoside in Comparative Examples 9 and 10 replace polyglyceryl-10 diisostearate in Example 5, the sustained release effect is not as good as that in Example 5, and the sustained release effect of Example 5 is more significant.

[0179] Depend on Figure 3 It can be seen that the release rate of mandelic acid in Example 5 is significantly faster than that of phenethyl resorcinol (377). At 2 hours, the cumulative release percentage of mandelic acid is 50.9%, while the cumulative release percentage of phenethyl resorcinol is only 14.7%, which also shows that mandelic acid in the external water phase is released faster than phenethyl resorcinol 377 in the internal oil phase. The results show that this whitening composition system achieves a graded release effect.

[0180] Test Example 2 Encapsulation efficiency and drug loading test

[0181] The encapsulation efficiency of phenethylresorcinol (377) and mandelic acid in the whitening nanocomposition was determined by ultrafiltration centrifugation. The whitening synergistic composition for lightening spots and scars prepared in Example 5, Comparative Example 9 and Comparative Example 10 was diluted 5 times with PBS solution, and 0.4 mL was placed in an ultrafiltration centrifuge tube (molecular weight cutoff 3 kDa). The filtrate was collected after centrifugation at 5000 r / min for 15 min. The contents of phenethylresorcinol and mandelic acid in the whitening synergistic composition for lightening spots and scars were determined by HPLC, i.e., the content of free phenethylresorcinol or mandelic acid W F Take another 0.4 mL of the diluted spot-lightening and whitening synergistic composition, add methanol to break the emulsion, centrifuge and determine the contents of phenethyl resorcinol and mandelic acid in the supernatant, which is the total phenethyl resorcinol or mandelic acid content W T The drug loading efficiency (DLE) and encapsulation efficiency (EE) of the spot-lightening, mark-lightening and whitening synergistic composition were calculated according to the following formula:

[0182]

[0183]

[0184] W T : Total phenylethyl resorcinol or mandelic acid mass, W F : Mass of free phenylethyl resorcinol or mandelic acid, W L Represents the mass of nanocarriers.

[0185] According to HPLC, the encapsulation rate of phenethyl resorcinol in the spot-lightening and whitening synergistic composition prepared in Example 5 is 92.4%, and the drug loading is 4.62%; the encapsulation rate of mandelic acid in the spot-lightening and whitening synergistic composition prepared in Example 5 is 88.9%, and the drug loading is 6.22%. The encapsulation rate of phenethyl resorcinol in the spot-lightening and whitening synergistic composition prepared in Comparative Example 9 is 61.7%, and the drug loading is 3.09%, and the encapsulation rate of mandelic acid is 54.6%, and the drug loading is 3.82%. The encapsulation rate of phenethyl resorcinol in the spot-lightening and whitening synergistic composition prepared in Comparative Example 10 is 64.4%, and the drug loading is 3.22%, and the encapsulation rate of mandelic acid is 57.3%, and the drug loading is 4.01%.

[0186] Combining Test Example 1 and Test Example 2, it can be seen that the process of the present invention can achieve both graded release of the double-layer packaging system and a higher encapsulation rate.

[0187] Test Example 3: Security Test

[0188] 1. Cell safety evaluation

[0189] The cell safety of the nanocomposite was determined by CCK-8 method. HaCaT cells in logarithmic growth phase were collected and cultured at 1.5×10 4 The density of HSF cells was 1.0×10 4 The density of cells / well was 100 μL per well, and the cells were inoculated in 96-well plates, respectively, and cultured at 5% CO2 and 37°C for 24 hours. 100 μL of DMEM complete medium (manufacturer, Gibco) containing different concentrations of the nanocomposition prepared in Example 5 or the whitening composition prepared in Comparative Examples 1 to 3 was added to each well, and only 100 μL of DMEM complete medium was added to the blank control group, and 3 replicates were added to each group. After continuing to culture for 24 hours, the cell survival rate was measured by CCK-8 method, and the cell safety results are shown in Figure 4 .

[0190] The experimental results show that within the concentration range of 50-200 μg / mL, the spot-lightening and whitening synergistic composition prepared in Example 5, the spot-lightening and whitening synergistic composition prepared in Comparative Examples 1 and 2, or the free whitening composition prepared in Comparative Example 3 are non-toxic to HaCaT and HSF cells; when the concentration is 400, 800, and 1200 μg / mL, the activity of HaCaT and HSF cells in Example 5 is significantly higher than that in Comparative Example 3. The results show that the spot-lightening and whitening synergistic composition prepared in Example 5 of the present invention can reduce the toxicity of whitening functional components.

[0191] 2. Evaluation of chicken embryo allantoic membrane irritation (10% high concentration example safety study)

[0192] 0.2 mL of 10% whitening and synergistic composition for lightening spots and scars prepared in Example 5, whitening and synergistic composition for lightening spots and scars prepared in Comparative Example 1 or Comparative Example 2, or free whitening composition sample prepared in Comparative Example 3 (prepared with normal saline) was taken and dripped onto the surface of chorioallantoic membrane, and the changes of CAM blood vessels were observed within 5 min, and the initial time of congestion, bleeding and coagulation of CAM blood vessels was recorded, and the stimulation score IS was calculated.

[0193] IS=[(301-secH)×5+(301-secL)×7+(301-secC)×9] / 300

[0194] Wherein, secH is the initial time of surface congestion, s; secL is the initial time of surface bleeding, s; secC is the initial time of surface coagulation, s.

[0195] The mean of repeated tests was calculated, and the irritation of the test substances was graded according to the size of the mean, with 0-0.9, 1.0-4.9, 5.0-8.9 and 9-21.0 being classified as no irritation, slight irritation, moderate irritation and severe irritation, respectively.

[0196] The results show that when the spot-lightening and whitening synergistic composition prepared in Example 5 after being diluted 10 times, the spot-lightening and whitening synergistic composition prepared in Comparative Examples 1 and 2, or the free whitening composition prepared in Comparative Example 3 are in contact with the chicken embryo chorioallantoic membrane for 300 seconds, there is no bleeding in the capillaries, no vascular melting, and no coagulation phenomenon, which is non-irritating. This shows that the spot-lightening and whitening synergistic composition prepared in Example 5 after being diluted 10 times, the spot-lightening and whitening synergistic composition prepared in Comparative Examples 1 and 2, or the free whitening composition prepared in Comparative Example 3 have good safety.

[0197] 3. Patch test (10% high concentration example safety study)

[0198] 31 subjects were selected in the experiment and their responses were recorded. 10% of the spot-lightening and whitening synergistic composition prepared in Example 5, Comparative Example 1, Comparative Example 2 or the free whitening composition prepared in Comparative Example 3 was placed in the spot tester, and the normal well was used as a blank control. The formula of the patch cream is as follows: by mass percentage, 2.0% PEC-10 polydimethylsiloxane, 1.0% sucrose stearate, 1.0% stearyl alcohol, 4.5% monostearate glyceryl enzyme, 1.0% cetostearyl alcohol, and 3.0% jojoba oil are melted in a 75°C water bath to obtain an oil phase; 5.0% glycerol, 5.0% propylene glycol, 0.3% triethanolamine, 0.2% carbomer 2020 and 67.0% purified water are dissolved in a 75°C water bath to obtain an aqueous phase; the oil phase and the aqueous phase are stirred and mixed, and emulsified, and the temperature is lowered to 40°C with continuous stirring, and then 10% of the spot-lightening and whitening synergistic composition or the free whitening composition is added, and stirred evenly to obtain the patch cream.

[0199] The samples and blank controls were applied to the curved side of the forearm of the subjects, and the samples were evenly applied to the skin by lightly pressing with the palm of the hand for 24 hours. After removing the spot tester, the skin reaction was observed after a 30-minute interval after the indentation disappeared. The skin reaction was observed again 24 hours and 48 hours after the spot tester was removed. The results are shown in Table 2.

[0200] The results showed that none of the 31 subjects developed light red spots, erythema, edematous erythema, significant redness and swelling, infiltration or papules, and papules or blisters, etc., indicating that the whitening composition in this test is non-irritating to human skin.

[0201] Table 2 Results of cosmetics occluded patch test on human skin

[0202]

[0203] Test Example 4 Target Site Release Behavior Test

[0204] (1) Effect of lipase on in vitro release behavior

[0205] The dialysis bag method was used to study the effect of lipase on the in vitro release behavior of the spot-lightening and whitening synergistic composition prepared in Example 5. The dialysis bag (molecular weight cutoff of 3500Da) was boiled with ultrapure water for 5 minutes and soaked in 50% ethanol solution overnight before use. 2g of different spot-lightening and whitening synergistic compositions were placed in the dialysis bag, sealed at both ends with dialysis bag clips, and placed in a blue-mouthed bottle containing 80mL of release medium. The release media were 20% propylene glycol PBS solution and 0.2% lipase and 20% propylene glycol PBS solution. The samples of different release media were shaken at 37°C and 100rpm in a shaker for 12h. 1mL of samples were taken at 1, 2, 4, 6, 8, 10 and 12h, and the same volume of release medium was immediately added. The HPLC method was used to determine the concentrations of phenethylresorcinol and mandelic acid in the samples at different time points, and the cumulative release percentages of phenethylresorcinol (377) and mandelic acid were calculated. The experimental results are shown in Figure 5 .

[0206] The experimental results show that, compared with the release medium without lipase, the release medium containing 0.2% lipase by mass has a more significant promoting effect on the in vitro release of phenethyl resorcinol (377) and mandelic acid in Example 5. This indicates that in the presence of lipase, the oil ester in the spot-lightening and scar-lightening whitening synergistic composition prepared in Example 5 is hydrolyzed by lipase to quickly release phenethyl resorcinol (377) and mandelic acid, among which the accelerated release of mandelic acid is more significant. The Chinese patent with publication number CN 114177116 B also mentions that the lipase activity will increase at the site of acne inflammation. Therefore, in this example, it can be explained that mandelic acid can be quickly released at a high concentration at the site of inflammation, and can then more efficiently exert its active effect to help lighten the pigmentation that has already formed.

[0207] Test Example 5 In vitro skin permeation test

[0208] (1) Determination of cumulative permeation and skin retention

[0209] The vertical Franz diffusion cell method was used to conduct an in vitro pig skin transdermal experiment. The skin was fixed between the receiving chamber and the supply chamber, and 0.5 g of each of the free whitening composition prepared in Comparative Example 3 and the spot-lightening and whitening synergistic composition prepared in Example 5 were taken into the supply chamber, and PBS (pH 7.4) was used as the receiving solution, and stirred and diffused at 37°C. 0.5 mL of receiving solution was taken at 2, 4, 6, 8, 12 and 24 h, and an equal amount of constant temperature fresh receiving solution was immediately supplemented. HPLC analysis was performed to calculate the cumulative permeation amount per unit area of ​​phenethylresorcinol (377) and mandelic acid at different times. After 24 h, the skin was removed, washed, cut into pieces, ground into a homogenate, an appropriate amount of receiving solution was added and centrifuged, and the supernatant was taken for HPLC analysis to calculate the skin retention amount per unit area of ​​phenethylresorcinol (377) and mandelic acid. The experimental results are shown in Figure 6 .

[0210] Depend on Figure 6 It can be seen that the 24-hour cumulative skin permeation per unit area of ​​377 in Comparative Example 3 and Example 5 is 15.6 μg / cm 2 and 43.7 μg / cm 2 , and the skin retention was 18.2 μg / cm 2 and 66.4 μg / cm 2 Compared with Comparative Example 3, the cumulative permeation per unit area of ​​377 in Example 5 increased by 180.1%, and the skin retention increased by 264.8%. The 24h cumulative permeation per unit area of ​​mandelic acid in Comparative Example 3 and Example 5 were 63.4 μg / cm 2 and 132.8 μg / cm 2 , and the skin retention was 84.7 μg / cm 2 and 276.4 μg / cm 2 Compared with comparative example 3, the cumulative amount of mandelic acid permeated per unit area of ​​skin in example 5 increased by 109.5%, and the amount of skin retention increased by 226.3%. The results show that the composition prepared by the process of the present invention can effectively promote the transdermal absorption of the functional ingredients and the amount of retention in the skin, and improve its skin bioavailability.

[0211] (2) Laser confocal microscopy to observe skin penetration

[0212] The vertical Franz diffusion cell method was used to conduct a transdermal experiment on ex vivo pig skin. The skin was fixed between the receiving chamber and the supply chamber, RhoB (added at 0.1%) was encapsulated in the external aqueous phase as a water-soluble dye, and FITC (added at 0.1%) was encapsulated in the intermediate oil phase as a fat-soluble dye. The corresponding compositions were prepared according to the methods described in Example 5 and Comparative Example 3: RhoB-FITC spot-lightening and whitening synergistic composition and RhoB-FITC free whitening composition. 0.5 g of each sample was placed in the supply chamber, PBS was used as the receiving solution, and the mixture was stirred and diffused at 37°C. After 2h and 4h, the residual sample on the skin was gently wiped off, the skin in the target area was removed, the skin was rinsed again, and the residual moisture was wiped off after thorough cleaning. The sample was frozen and sectioned, and the sections were observed under a laser confocal microscope, and representative areas were selected and photographed. See the results. Figure 7 .

[0213] Depend on Figure 7 It can be seen that with the extension of penetration time, the fluorescence intensity of RhoB and FITC in the skin is enhanced. RhoB and FITC in the RhoB-FITC free whitening composition are mostly concentrated in the stratum corneum at 2 hours and fail to penetrate the stratum corneum barrier. RhoB in the RhoB-FITC spot-lightening and whitening synergistic composition has penetrated the stratum corneum barrier at 2 hours, and the FITC fluorescence intensity is enhanced compared to the free one. At 4 hours, the fluorescence intensity and penetration depth of the skin increase. The results show that the preparation process of this invention can promote the rapid delivery of the encapsulated ingredients to the deep tissues of the skin.

[0214] Test Example 6 Target site cell uptake test

[0215] (1) Observation of cell uptake behavior using laser confocal microscopy

[0216] An appropriate amount of RhoB dye (added at 0.1%) was weighed as a fluorescent marker, and the corresponding RhoB spot-lightening and whitening synergistic composition and RhoB free whitening composition were prepared according to the methods described in Example 5 and Comparative Example 3. B16F10 cells (comparable to melanin target cells below the basal layer) and HaCaT cells (comparable to keratinocytes above the basal layer) in the logarithmic growth phase were respectively placed at 3×10 5 After 24 hours of inoculation of cells in a 35 mm confocal dish, DMEM medium containing 0.1% RhoB free whitening composition or 0.1% RhoB spot lightening and whitening synergistic composition was added and incubated for 4 hours. After incubation, the medium was discarded and the cells were washed 3 times with PBS solution, fixed with 4% paraformaldehyde and stained with DAPI solution for 15 minutes each, and observed and photographed under a 60x objective lens using a laser confocal microscope. The results are shown in Figure 8 .

[0217] Depend on Figure 8It can be seen that with the extension of incubation time, the fluorescence intensity of B16F10 cells and HaCaT cells increased significantly. Figure 8 The fluorescence intensity of B16F10 cells and HaCaT cells in the group with free RhoB in the medium was weak, while that in the group with RhoB spot-lightening and whitening synergistic composition ( Figure 8 The fluorescence of the RhoB nanocarrier group has entered the cells, and the fluorescence intensity is significantly stronger than that of free RhoB. After incubation for 4 hours, the fluorescence intensity of the RhoB nanocarrier group is further enhanced, and the fluorescence intensity of B16F10 cells (melanin target cells) is stronger than that of HaCaT cells. The experimental results show that compared with the RhoB free whitening composition, the RhoB spot-lightening and whitening synergistic composition can be more taken up by B16F10 cells and HaCaT cells, and compared with HaCaT cells, B16F10 (melanin target cells) cells take up more, revealing that the spot-lightening and whitening synergistic composition provided by the present invention can effectively deliver the encapsulated active substances into the skin target cells to exert the whitening effect.

[0218] (2) Flow cytometry to detect cell uptake behavior

[0219] B16F10 cells and HaCaT cells were cultured at 2 × 10 5 The cells were seeded in a 6-well plate at a density of 100 cells and incubated for 24 hours to allow the cells to adhere to the wall. The old culture medium was discarded, and then the composition prepared in (1) was added to each well. The cells without any treatment were used as negative controls. After further culture for 2 hours and 4 hours, the cells were washed with cold PBS, digested with trypsin, centrifuged, and the cell pellets were collected and resuspended in 0.5 mL of cold PBS solution. The intracellular fluorescence intensity was detected by flow cytometry. The results are shown in Fig. 9 and Fig.10 .

[0220] Depend on Fig. 9 It can be seen that after incubation for 2h and 4h, the RhoB spot-lightening and whitening synergistic composition ( Fig. 9 The average fluorescence intensity of B16F10 cells in the RhoB nanocarrier-treated group was 4832 and 7655, respectively, which was significantly lower than that in the RhoB free whitening composition ( Fig. 9 Compared with the free RhoB group, the average fluorescence intensity of the HaCaT cells in the RhoB whitening and enhancing composition group was increased by 202.4% and 112.8%, respectively. After incubation for 2h and 4h, the average fluorescence intensity of the HaCaT cells in the RhoB whitening and enhancing composition group was 3297 and 5973, respectively, which was increased by 222.9% and 230.7%, respectively, compared with the RhoB free whitening composition group. The experimental results show that the whitening and enhancing composition provided by the present invention can significantly enhance the cellular uptake and intracellular accumulation of its encapsulated materials by B16F10 cells and HaCaT cells.

[0221] Depend on Fig.10 It can be seen that after incubation for 2h and 4h, the average fluorescence intensity of B16F10 cells (melanin target cells) is stronger than that of HaCaT cells, and the results are basically consistent with the above-mentioned laser confocal uptake results. Therefore, through this test example, it can be proved that the whitening and synergistic composition of the double-layer encapsulation system obtained by the present invention can reach the target site of melanocytes in the basal layer, and can better play the role of inhibiting the production of melanin.

[0222] It can be seen from Test Examples 1 to 6 that the present invention successfully prepared a smear-lightening and whitening synergistic composition with a double-layer packaging system and a targeted transdermal delivery function that can be released in stages at the target site, and can even penetrate into the target cell site more efficiently, thereby helping to exert the whitening effect more efficiently.

[0223] The following test examples focus on demonstrating from multiple dimensions that the double-layer packaging system prepared by the present invention has a targeted transdermal delivery function and has a good whitening effect, and can help effectively fight pigmentation such as spots and acne marks.

[0224] Test Example 7 Cell Efficacy Test

[0225] (1) In vitro 2D melanocyte model validation - intracellular tyrosinase activity assay

[0226] The activity of intracellular tyrosinase was determined by L-Dopa oxidation method. Mouse melanoma cells (B16F10) were taken at 1×10 5 / mL was inoculated in a 24-well plate, 1mL per well, and cultured for 24h. According to the experimental grouping, 100nM α-MSH was added for induction (except the normal control group), and an α-MSH-induced melanin high expression model was constructed, and then the spot-lightening and whitening synergistic composition prepared in Example 1, Example 2 and Example 5 was added, with a content of 100μg / mL. The active substance concentrations of Comparative Examples 1, 2 and 3 were the same as those of Example 5, and 3 duplicate wells were set for each group. After 48h of culture, the supernatant was discarded, washed 3 times with PBS, 300μL of PBS buffer containing 1% TritonX-100 was added to each well, placed in a -80℃ refrigerator for 1h, then thawed at room temperature, the cell lysate was centrifuged at 12000rpm for 20min, and the supernatant was collected. Take 60 μL of the supernatant in a 96-well plate, add 140 μL of 0.1% L-Dopa, incubate at 37°C for 1 hour, and measure the absorbance (A) of each well at a wavelength of 490 nm. Fig.11 .

[0227] Depend on Fig.11It can be seen that compared with the model group, Comparative Example 1, Comparative Example 2, Comparative Example 3, Example 1 and Example 5 can all significantly reduce tyrosinase activity. Compared with Comparative Example 1, Example 1 and Example 5 have a more significant effect on reducing tyrosinase activity in B16F10 cells (P<0.01). Compared with Comparative Example 2, Example 1 and Example 5 have a more significant effect on reducing tyrosinase activity in B16F10 cells (P<0.01). Compared with Comparative Example 3, Example 1 and Example 5 have a more significant effect on reducing tyrosinase activity in B16F10 cells (P<0.01). The results showed that the tyrosinase activity of the free component (Comparative Example 3) was 57%; mandelic acid and nonapeptide-1 were wrapped in the outer water phase (i.e., the outermost layer), and phenethyl resorcinol, palmitoyl tetrapeptide-7, and acetyl dipeptide-1 cetyl ester were wrapped in the inner oil phase (Comparative Example 2) (i.e., the innermost layer) with a tyrosinase activity of 43%; mandelic acid and phenethyl resorcinol were wrapped in the inner oil phase, nonapeptide-1, palmitoyl tetrapeptide-7, and acetyl dipeptide-1 cetyl ester were wrapped in the outer water phase (Comparative Example 1) with a tyrosinase activity of 50%; 1% nonapeptide-1, 10% phenethyl resorcinol, 1% palmitoyl tetrapeptide-7, 1% acetyl dipeptide-1 cetyl ester The tyrosinase activity of acetyl dipeptide-1 cetyl ester and 10% mandelic acid (Example 1) is 20%; the tyrosinase activity of 0.01% nonapeptide-1, 1% phenethyl resorcinol, 0.01% palmitoyl tetrapeptide-7, 0.01% acetyl dipeptide-1 cetyl ester and 1% mandelic acid (Example 2) is 69%; mandelic acid is wrapped in the outer water phase, phenethyl resorcinol, palmitoyl tetrapeptide-7, acetyl dipeptide-1 cetyl ester are wrapped in the middle oil phase, and nonapeptide-1 is wrapped in the inner water phase (Example 5) The tyrosinase activity is 34%, and compared with Comparative Example 3, the tyrosinase activity of Example 5 is reduced by 40%. It is proved that under the same active substance concentration conditions, mandelic acid is wrapped in the outer water phase, phenethyl resorcinol, palmitoyl tetrapeptide-7, acetyl dipeptide-1 cetyl ester are wrapped in the middle oil phase, and nonapeptide-1 is wrapped in the inner water phase, which can promote the effect of whitening efficacy ingredients.

[0228] (2) In vitro 2D melanocyte model validation - effect on cellular melanin production

[0229] The NaOH lysis method was used to determine the content of black in cells. B16F10 cells were taken at 5×10 4 / mL were inoculated in a 6-well plate, 2mL per well, and cultured for 24h. 100nM α-MSH was added for induction according to the experimental groups (except the normal control group), and an α-MSH-induced melanin high expression model was constructed, and then the spot-lightening and whitening synergistic composition prepared in Example 1, Example 2 and Example 5 was added, with a content of 100μg / mL. The active ingredient concentrations of Comparative Examples 1, 2 and 3 were the same as those in Example 5. After 48h of culture, the supernatant was discarded, and the cells were washed 3 times with PBS. 300μL of 1.0mmol / L NaOH solution (containing 10% DMSO) was added to each well, and the cells were fully lysed at 80℃ for 1h, and the absorbance (A) of each well was measured at a wavelength of 405nm. The results are shown in Fig.12 .

[0230] Depend on Fig.12 It can be seen that compared with the model group, Comparative Example 1, Comparative Example 2, Comparative Example 3, Example 1, Example 2 and Example 5 can all significantly reduce the intracellular melanin content. Compared with Comparative Example 1, Example 1 and Example 5 have a more significant effect on reducing the intracellular melanin content of B16F10 cells (P<0.01). Compared with Comparative Example 2, Example 1 and Example 5 have a more significant effect on reducing the intracellular melanin content of B16F10 cells (P<0.01). Compared with Comparative Example 3, Example 1 and Example 5 have a more significant effect on reducing the intracellular melanin content of B16F10 cells (P<0.01). The results show that the melanin content of the free component (Comparative Example 3) is 69%, mandelic acid and nonapeptide-1 are wrapped in the outer water phase, and phenethyl resorcinol, palmitoyl tetrapeptide-7, and acetyl dipeptide-1 cetyl ester are wrapped in the inner oil phase (Comparative Example 2) The melanin content is 54%; mandelic acid and phenethyl resorcinol are wrapped in the inner oil phase, nonapeptide-1, palmitoyl tetrapeptide-7, and acetyl dipeptide-1 cetyl ester are wrapped in the outer water phase (Comparative Example 1) The melanin content is 66%; mandelic acid is wrapped in the outer water phase, phenethyl resorcinol, palmitoyl tetrapeptide-7, and acetyl dipeptide-1 cetyl ester are wrapped Wrapped in the middle oil phase, 1% nonapeptide-1, 10% phenethyl resorcinol, 1% palmitoyl tetrapeptide-7, 1% acetyl dipeptide-1 cetyl ester, 10% mandelic acid (Example 1) has a melanin content of 24%; 0.01% nonapeptide-1, 1% phenethyl resorcinol, 0.01% palmitoyl tetrapeptide-7, 0.01% acetyl dipeptide-1 cetyl ester, 1% mandelic acid (Example 2) has a melanin content of 75%; nonapeptide-1 is wrapped in the inner water phase (Example 5) with a melanin content of 43%, and compared with Comparative Example 3, the melanin content of Example 5 is reduced by 38%. It is proved that under the condition of the same active substance concentration, oleomandelic acid is wrapped in the outer water phase, phenethyl resorcinol, palmitoyl tetrapeptide-7, and acetyl dipeptide-1 cetyl ester are wrapped in the middle oil phase, and nonapeptide-1 is wrapped in the inner water phase, which can promote the effect of whitening efficacy ingredients.

[0231] (3) In vitro 2D inflammatory cell model validation - determination of cellular inflammatory factors

[0232] RAW264.7 cells were cultured at 1.0 × 10 5 The cells were inoculated into a 24-well cell culture plate at a density of 0.5 mL per well. After culturing for 24 hours, 1 μg / mL of LPS was added to the cells of the other groups except the blank control group to establish a cell inflammation model. Only 1 μg / mL of LPS was added to the cells of the model group to establish a cell inflammation model. 1 μg / mL of LPS and 0.5 mL of the whitening and synergistic composition prepared by Comparative Examples 4 to Comparative Examples 8 and Example 5 (test concentration of 0.01%) were added to each sample experimental group, and the culture was continued at 37°C for 24 hours. The upper culture fluid was collected and the expression levels of IL-6 and TNF-α were detected according to the instructions of the ELISA kit. The results are shown in Table 3.

[0233] As shown in Table 3, compared with the blank control group, the expression of IL-6 and TNF-α in the model group increased significantly after the addition of LPS (p<0.01); compared with the model group, the whitening and synergistic compositions prepared by Comparative Examples 4 to 8 and Example 5 can significantly reduce the expression of IL-6 and TNF-α (p<0.01). Among them, the whitening and synergistic composition prepared by Example 5 has a more significant effect on inhibiting the secretion of IL-6 and TNF-α by Raw264.7 cells than Comparative Examples 4 to 8, indicating that the whitening and synergistic composition contains 0.02% palmitoyl tetrapeptide-7 and 0.02% acetyl dipeptide-1 cetyl ester, and the effect of inhibiting inflammation is the best, which is better than the whitening and synergistic composition containing 0.02% acetyl tetrapeptide-15 and 0.02% palmitoyl tripeptide-8. It is speculated that the two peptides contained in Example 5 have better anti-allergic and anti-inflammatory effects.

[0234] Table 3 Effects on the expression of inflammatory factors

[0235]

[0236] Note: Compared with the blank control group, ## p<0.01; compared with the model group, ** p<0.01; compared with Example 5, && p<0.01;

[0237] Test Example 8: Whitening efficacy test of the innovative 2D zebrafish model in vitro

[0238] Based on whitening efficacy screening: T / SHRH036-2021 "Cosmetic Melanin Inhibition Test-Zebrafish Embryo Test Method". 24 8-hour-old zebrafish embryos were exposed to 0.1% test concentration of Example 5 sample solution. A blank control group, a 100% melanin inhibition model group (30 mg / L phenylthiourea) and a positive control group (2.5 g / L kojic acid) were set up at the same time. After 48 hours of exposure, the fish embryos were photographed under a microscope to measure the melanin signal intensity and perform statistical analysis. Results are shown in Fig.13 .

[0239] Depend on Fig.13 It can be seen that Example 5 has a significant effect of inhibiting the production of melanin in zebrafish embryos, and its melanin production inhibition rate is 21%, which is comparable to the melanin production inhibition effect of kojic acid with a concentration 2.5 times higher. It can be seen that the double-layer encapsulation system of the whitening and lightening composition prepared by the present invention has a whitening effect.

[0240] Test Example 9 Whitening effect test of 3D skin melanin model

[0241] 3D Melanin Skin Model The negative control, positive control (kojic acid 500 μg / mL) and sample group (the spot-lightening and whitening synergistic composition prepared in Example 5, with a content of 5 mg / mL, and the active ingredient concentrations of Comparative Examples 1, 2 and 3 are the same as those in Example 5) were irradiated with UVB (50 mJ / cm 2 ), and the blank control was not irradiated with UVB. The positive control group and the sample group were administered twice on the 3rd and 5th days, respectively, with a dosing volume of 10 μL. After the model was cultured for 7 consecutive days, the apparent brightness (L* value) and melanin content of the 3D skin melanin model were tested. The results are shown in Fig.14 .

[0242] Depend on Fig.14 As shown in (A), compared with the blank group, the apparent brightness of each group after UVB irradiation treatment was significantly reduced (P<0.01). Compared with the model group, Comparative Example 1, Comparative Example 2, Comparative Example 3 and Example 5 can significantly improve the apparent brightness. Compared with Comparative Example 1, the apparent brightness of Example 5 is more significantly improved (P<0.01). Compared with Comparative Example 2, the apparent brightness of Example 5 is more significantly improved (P<0.01). Compared with Comparative Example 3, the apparent brightness of Example 5 is more significantly improved (P<0.01).

[0243] Depend on Fig.14As shown in (B), compared with the blank group, the melanin content of each group after UVB irradiation treatment was significantly increased (P<0.01). Compared with the model group, comparative examples 1, 2, 3 and 5 can significantly reduce the melanin content. Compared with comparative example 1, the melanin content of example 5 was reduced more significantly (P<0.01). Compared with comparative example 2, the melanin content of example 5 was reduced more significantly (P<0.01). Compared with comparative example 3, the melanin content of example 5 was reduced more significantly (P<0.01).

[0244] The results show that the free component (Comparative Example 3) has an L* value of 61% and a melanin content of 26 μg / mL; mandelic acid and nonapeptide-1 are wrapped in the outer water phase, and phenethyl resorcinol, palmitoyl tetrapeptide-7, and acetyl dipeptide-1 cetyl ester are wrapped in the inner oil phase (Comparative Example 2) with an L* value of 65% and a melanin content of 21 μg / mL; mandelic acid and phenethyl resorcinol are wrapped in the inner oil phase, nonapeptide-1, palmitoyl tetrapeptide-7, and acetyl dipeptide-1 cetyl ester are wrapped in the inner oil phase. The wax ester is wrapped in the outer water phase (Comparative Example 1), the L* value is 63%, and the melanin content is 23μg / mL; the mandelic acid is wrapped in the outer water phase, phenylethyl resorcinol, palmitoyl tetrapeptide-7, acetyl dipeptide-1 cetyl ester is wrapped in the middle oil phase, and nonapeptide-1 is wrapped in the inner water phase (Example 5), the L* value is 71%, and the melanin content is 18μg / mL. Compared with Comparative Example 3, the L* value of Example 5 is increased by 16% and the melanin content is reduced by 31%. It is proved that the mandelic acid is wrapped in the outer water phase, phenylethyl resorcinol, palmitoyl tetrapeptide-7, acetyl dipeptide-1 cetyl ester is wrapped in the middle oil phase, and nonapeptide-1 is wrapped in the inner water phase, which can promote the effect of the whitening effect ingredients.

[0245] Test Example 10 Peeling Test

[0246] After the pig skin was thawed and cleaned, the skin was fixed between the supply chamber and the receiving chamber of the Franz cell diffusion cell, with the skin stratum corneum facing the supply chamber and the dermis facing the receiving chamber; 7.0 mL of receiving solution (PBS, pH 7.4) was added to the receiving chamber, and after the suckling pig skin was tightened and fixed, 1.5 mL of receiving solution (PBS) was added to the receiving chamber through a sampler, and the air was exhausted to make the skin dermis layer in close contact with the receiving solution. 50 μL of 100 mg / mL salicylic acid (solvent was PBS, positive control sample), 50 μL of the spot-lightening and whitening synergistic composition prepared in Example 5 (with mandelic acid concentration of 70 mg / mL), 50 μL of the free whitening composition prepared in Comparative Example 3 (with mandelic acid as the active substance, and its concentration is the same as that in Example 5) and 50 μL of PBS buffer (blank control sample) were added to the skin surface in the supply chamber, and then the above samples were evenly spread from the center of the skin to the edge in a radial shape, and the sample exposure area was 3.14 cm 2. Each sample was repeated 3 times in parallel, and a constant temperature water bath of (32±1)℃ was maintained, and it was ensured that there were no bubbles in the water bath interlayer. After incubation for 30 minutes, put on finger cots and rub the sample application area. After rubbing for two minutes, add 0.5mL of cleaning solution (0.1% Triton X) to the supply chamber, and blow and clean the keratinocytes shed from the skin surface. Transfer the cleaning solution to a 1.5mL centrifuge tube for BCA protein determination. The total protein content was detected according to the instructions of the BCA protein assay kit. After the sample is treated, rub and clean the skin surface, lyse the eluted keratinocytes, and detect the total protein content in the lysate. The results are summarized in the table Fig.15 .

[0247] Depend on Fig.15 It can be seen that compared with the blank control group, the total protein content of the keratinocytes of the positive control group significantly increased, indicating that the number of keratinocytes shed increased significantly, and the positive control detection of this test was effective. Compared with the blank control group, after treating the skin, the total protein content of the keratinocytes shed on the skin surface of Example 5 and Comparative Example 3 increased significantly (P < 0.01), indicating that the number of keratinocytes shed increased significantly, indicating that Example 5 and Comparative Example 3 can achieve the exfoliation effect by increasing the shedding of keratinocytes, and the protein shedding lifting rate is 205.77% and 232.69% respectively. It can be seen that in the preparation process of the present invention, although the outermost layer in Example 5 is immediately processed by wrapping, it is still possible to play a keratin exfoliation effect, and the exfoliation effect is not much different from that of free mandelic acid. It can be seen that the double-layer wrapped whitening synergistic composition prepared by the present invention can play a good role in fading the melanin deposited in the epidermal stratum corneum, and can help acne people to play an accelerated light black effect.

[0248] Application Example 1 Human whitening test (test concentrations of 1% and 3%)

[0249] The whitening composition was made into a whitening essence according to the formula framework in Table 4, and a human whitening test was arranged. 33 subjects aged 23 to 39 years (27.18±2.95) with facial spots and acne marks were tested. The left and right halves of the face were randomly used with the test product every morning and evening for 28 days, and the spots and acne marks were observed. The melanin lightening situation was mainly monitored. The test results are shown in Table 5. As can be seen from Table 5, the long-term lightening effect of Example 5 was explored. At the two concentrations of Example 5, after 28 days, the melanin at the acne marks and spots had a lightening effect, and as the use time increased, the effect of lightening melanin was gradually increasing. It can be seen that Example 5 has the effect of lightening dark brown acne marks and spots, that is, it can play a whitening effect.

[0250] Table 4 Whitening Essence Formula

[0251]

[0252]

[0253] Table 5 Summary of 28-day whitening test results

[0254]

[0255] The preferred embodiments of the present invention disclosed above are only used to help explain the present invention, but the present invention is not limited thereto. Those skilled in the art can understand that within the technical concept of the present invention, the technical solution of the present invention can be modified, or some technical features can be combined in any other way. These modifications or combinations do not make the essence of the corresponding technical solution deviate from the spirit and scope of each implementation of the technical solution of the present invention, and should be regarded as the contents disclosed by the present invention, which belong to the protection scope of the present invention.

Claims

1. A spot-lightening, scar-lightening, whitening and synergistic composition containing mandelic acid and having a targeted transdermal delivery function, characterized in that: It is formed by an inner water phase, an oil phase and an outer water phase; The internal aqueous phase includes an α-MSH antagonist; The oil phase includes phenylethyl resorcinol, palmitoyl tetrapeptide-7, acetyl dipeptide-1 cetyl ester, emulsifier, neutral phospholipids and oil; The external aqueous phase includes a keratin exfoliant and a polyglycerol ester emulsifier; The exfoliating agent includes mandelic acid; The preparation method of the spot-lightening, scar-lightening and whitening synergistic composition containing mandelic acid and having a targeted transdermal delivery function comprises the following steps: S1) mixing an α-MSH antagonist with water to obtain an inner aqueous phase; Mixing phenylethyl resorcinol, palmitoyl tetrapeptide-7, acetyl dipeptide-1 cetyl ester, an emulsifier, a neutral phospholipid and oil to obtain an oil phase; Mixing a keratin exfoliant, a polyglycerol ester emulsifier and water to obtain an external aqueous phase; S2) adding the inner water phase dropwise to the oil phase and mixing to obtain a water-in-oil system; S3) adding the water-in-oil system dropwise to the external aqueous phase and mixing to obtain a water-in-oil-in-water emulsion; S4) micronizing the water-in-oil-in-water emulsion to obtain a micron-sized dispersion; S5) subjecting the micron-sized dispersion to nano-treatment to obtain a spot-lightening, scar-lightening, whitening and synergistic composition containing mandelic acid and having a targeted transdermal delivery function; The emulsifier is selected from polyoxyethylene hydrogenated castor oil; The polyglycerol ester emulsifier is selected from one or more of polyglyceryl-10 myristic acid ester, polyglyceryl-10 oleic acid ester, polyglyceryl-10 dipalmitate and polyglyceryl-10 diisostearate; The micronization process in step S4) is high-speed shearing; The nano-processing in step S5) is a high-pressure homogenization process or a high-pressure microfluidization process.

2. The spot-lightening, scar-lightening and whitening synergistic composition according to claim 1, characterized in that: The mass of the α-MSH antagonist is 0.01% to 1% of the mass of the spot-lightening, scar-lightening and whitening synergistic composition; The mass of the phenethyl resorcinol is 1% to 10% of the mass of the spot-lightening and whitening synergistic composition; The mass of the palmitoyl tetrapeptide-7 is 0.01% to 1% of the mass of the spot-lightening and whitening synergistic composition; The mass of the acetyl dipeptide-1 cetyl ester is 0.01% to 1% of the mass of the spot-lightening and whitening synergistic composition; The mass of the keratin peeling agent is 1% to 10% of the mass of the spot-lightening, scar-lightening and whitening synergistic composition.

3. The spot-lightening, scar-lightening and whitening synergistic composition according to claim 1, characterized in that: The mass ratio of phenethyl resorcinol, palmitoyl tetrapeptide-7 and acetyl dipeptide-1 cetyl ester is (1-10): (0.01-0.5): (0.01-0.5).

4. The spot-lightening, scar-lightening and whitening synergistic composition according to claim 1, characterized in that: The α-MSH antagonist is selected from one or more of nonapeptide-1, undecylenoyl phenylalanine and hexapeptide-2; The keratolytic agent also includes salicylic acid and / or capryloyl salicylic acid.

5. The spot-lightening, scar-lightening and whitening synergistic composition according to claim 1, characterized in that: The inner water phase also includes a first polyol; the outer water phase also includes a second polyol; The first polyol and the second polyol are each independently selected from one or more of glycerol, propylene glycol, butylene glycol, 1,2-pentanediol, 1,2-hexanediol, dipropylene glycol, PEG-10 propylene glycol and polyethylene glycol-400; The mass of the first polyol is 1% to 5% of the mass of the spot-lightening and whitening synergistic composition; The mass of the second polyol is 10% to 20% of the mass of the spot-lightening and whitening synergistic composition.

6. The spot-lightening, scar-lightening and whitening synergistic composition according to claim 1, characterized in that: The inner water phase also includes a first polyol; the outer water phase also includes a second polyol; The first polyol and the second polyol are each independently selected from one or more of glycerol, 1,3-propylene glycol, butylene glycol, 1,2-pentanediol, 1,2-hexanediol, dipropylene glycol, PEG-10 propylene glycol and polyethylene glycol-400; The mass of the first polyol is 1% to 5% of the mass of the spot-lightening and whitening synergistic composition; The mass of the second polyol is 10% to 20% of the mass of the spot-lightening and whitening synergistic composition.

7. The spot-lightening, scar-lightening and whitening synergistic composition according to claim 1, characterized in that: The mass of the emulsifier is 3% to 7% of the mass of the spot-lightening, scar-lightening and whitening synergistic composition; The mass of the neutral phospholipid is 1% to 5% of the mass of the spot-lightening and whitening synergistic composition; The neutral phospholipid is selected from one or more of lecithin, soybean lecithin, hydrogenated soybean lecithin, dimyristoylphosphatidylcholine, dioleoylphosphatidylcholine, phosphatidylethanolamine, dioleoylphosphatidylethanolamine, cephalin, and sphingomyelin; The mass of the oil is 1% to 5% of the mass of the spot-lightening, mark-lightening, whitening and synergistic composition; The oil is selected from one or more of caprylic / capric triglyceride, palmitic triglyceride, isopropyl palmitate, triethylhexanoin, isopropyl myristate, ethylhexyl cocoate, ethylhexyl palmitate, isoamyl laurate, squalane, olive oil, soybean oil and jojoba seed oil; The mass of the polyglycerol ester emulsifier is 1% to 5% of the mass of the spot-lightening and whitening synergistic composition.

8. The spot-lightening, scar-lightening and whitening synergistic composition according to claim 1, characterized in that: The dripping speed in step S2) and step S3) is independently 1-5 drops / s; the mixing speed in step S2) and step S3) is independently 10-60 rpm; The high-speed shearing speed is 4000-10000 rpm; the high-speed shearing time is 1-10 min; The pressure of the high-pressure homogenization treatment is 300-1600 bar; the number of cycles of the high-pressure homogenization treatment is 1-10 times; the pressure of the high-pressure microfluidization treatment is 5000-16000 psi; the number of cycles of the high-pressure microfluidization treatment is 1-10 times.

9. A cosmetic, characterized in that: A smear-lightening, scar-lightening and whitening synergistic composition comprising mandelic acid and having a targeted transdermal delivery function as described in any one of claims 1 to 8.

10. The cosmetic according to claim 9, characterized in that: The mass of the spot-lightening, scar-lightening, whitening and synergistic composition containing mandelic acid and having targeted transdermal delivery function is 0.01% to 10% of the mass of the cosmetics.

Citation Information

Cited By

  • Whitening and moisturizing composition and preparation method thereof

    CN121243027A

  • A whitening moisturizing composition and a method of preparing the same

    CN121243027B